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ABSTRACT
Diabetes mellitus (DM) imparts vascular and metabolic stressors that cause
damage and dysfunction to the human nervous system. The disorder associated with this
dysfunction is termed diabetic polyneuropathy (DPN). Although DPN has been
associated with muscle weakness and atrophy, the extent of its impacts on the
neuromuscular system is not well understood. The five studies presented in my thesis
investigated how DPN affects the neuromuscular system in humans, from the motor
neuron to skeletal muscle contractile properties, using a combination of
electromyography (EMG), dynamometry and magnetic resonance imaging (MRI)
techniques.
The purpose of Studies 1 and 2 was to determine whether the neurogenic loss of
motor units underlies the muscle weakness and atrophy associated with DPN, and to
investigate how these changes may differ in an upper and lower limb muscle. I
determined DPN patients feature reduced motor unit estimates (MUNEs) compared to
controls, and progression of motor unit loss in DPN may follow a distal to proximal or
nerve length-dependent pattern.
The purpose of Study 3 was to assess the stability of neuromuscular transmission
in patients with DPN compared with healthy controls, using a novel set of
electrodiagnostic parameters obtained via quantitative EMG. I determined DPN patients
have less stable neuromuscular transmission, and they feature intermittent conduction
failure at a relatively low contraction intensity.
The purpose of Study 4 was to investigate skeletal muscle contractile properties
and morphology in DPN patients. I determined DPN patients possess slowed muscle,
with greater proportional amounts of non-contractile intramuscular tissue compared to
controls.
The purpose of Study 5 was to explore the fatigability of DPN patients during a
sustained maximal voluntary contraction (MVC). I determined DPN patients have less
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endurance than controls, and their increased fatigability may be associated with
neuromuscular transmission failure.

Overall these foundational explorations greatly expand our knowledge of how
DPN can impact the neuromuscular system in humans. Furthermore, the studies
contained within my thesis may help direct further useful studies and strategies to
understand, and direct clinical support in those with DPN.

KEYWORDS
Diabetic polyneuropathy (DPN); human; motor nervous system; muscle; weakness;
motor unit; electromyography (EMG); fatigue; magnetic resonance imaging (MRI);
dynamometry
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Chapter 1
1

General Introduction

Voluntary movement is a fundamental attribute expressed by nearly all forms of
animal life. In humans, similar to many animals, this voluntary movement is
accomplished via activation and control of the neuromuscular system. Thus, given the
understandable reverence humanity places on movement, it comes as no surprise that
humans have been fascinated by the study of neuromuscular physiology for millennia.
With utmost brevity, this fascination manifests within the ancient writings of Hippocrates
and Galen; the musings of da Vinci and Vesalius during the European Renaissance; and
through the seminal discoveries of Galvani1, Duchenne2, Adrian & Bronk3,4, DennyBrown5, Sherrington6, Henneman7 and others during the 18th, 19th and 20th centuries. In
spite of the immense growth of our understanding, complete discernment of many
workings within neuromuscular physiology remain elusive. Particular among these
mysteries are questions concerning the impacts of disease on muscle and nerve. Deeper
understanding of the impacts of these diseases may eventually lead to improved
diagnostic methods and enhanced treatment options, as well as models of nature’s
experiments to help understand basic physiology. Hence it has been observed,
“Physiology is the stepchild of medicine. That is why Cinderella often turns out the
queen.” (Martin H. Fischer)

1.1

The Human Neuromuscular System and the Motor Unit
The primary function of the neuromuscular system is to provide humans with the

means for movement and locomotion. In parsimonious terms, the system is comprised of
(1) α motor neurons which innervate, and thus control, (2) skeletal muscle fibres. Motor
neurons are responsible for relaying signals, in the form of action potentials, from the
central nervous system (i.e. the brain and spinal cord) to skeletal muscle which initiates
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contraction. Muscle fibres are then responsible for contracting via the actomyosin
complex, thus generating the force necessary for movement.
Each individual α motor neuron and the muscle fibres that it innervates form the motor
unit (Figure 1.1): the fundamental functional contractile unit in neuromuscular
physiology6. The size of motor units varies greatly from unit to unit, and muscle to
muscle, from dozens of muscle fibres per unit (e.g. external rectus) to thousands of
muscle fibres per unit (e.g. medial gastrocnemius)8. The motor unit composition of a
muscle is thought generally to reflect that muscle’s function9. For example muscles
involved with fine, complex movements (i.e. hand muscles) are usually comprised of
many, relatively smaller motor units. In contrast, muscles involved with gross limb
movement (i.e. the knee extensors) usually consist of relatively fewer, larger motor
units8.

Figure 1.1 The motor unit.
Two individual motor units are depicted. The α-motor neuron cell bodies are located in
the ventral horn of the spinal cord. Neuron axons exit the ventral horn into the periphery
and synapse with their respective muscle fibres. Each motor unit is composed of an
individual α-motor neuron and all of the muscles fibres it innervates6.
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Under most conditions, when contracting voluntarily, smaller motor units tend to
be recruited prior to larger motor units, a concept coined the Henneman size
principle7,10,11. The general result of this principle is that relatively smaller, weaker,
slower, fatigue resistant muscle fibres are recruited first before larger, stronger, faster,
less fatigue-resistant muscle fibres. This forms one important aspect of the orderly
recruitment of muscle and is occasionally referred to as spatial summation3,4,12,13. In
contrast, temporal summation refers to the modulation of motor unit firing rate whereby
muscle force output is changed by increasing or decreasing the frequency at which motor
neurons signal muscle to contract3,4. These two processes work concurrently and in
concert with one another to allow for a high degree of smooth and graded control in
muscle force generation in conjunction with motor drive and coordination from spinal
and supraspinal levels.
Of course, the neuromuscular system features far greater complexity than is
outlined above and many questions remain unresolved. Investigating pathophysiological
alterations to nerve and muscle due to aging or disease (e.g. diabetic neuropathy) can
provide useful and unique avenues for further insight into basic neuromuscular
physiology and the capacities and limitations of the system.

1.2 Type 2 Diabetes and Diabetic Neuropathy
Type 2 diabetes mellitus (DM) is a metabolic disorder marked by high blood
sugar (hyperglycemia) associated with insulin resistance or a relative dearth of insulin14.
In comparison, type 1 DM is an autoimmune mediated disorder leading to a total loss of
insulin production due to the destruction of insulin-producing beta cells within the
pancreas14,15. Type 2 DM accounts for approximately 90% of all cases of DM, and is
closely associated with obesity, sedentarianism, and poor dietary habits16. Given its
greater prevalence and burden upon society, the study of type 2 DM and its neuropathic
complications will form the focus of this thesis. Thus, throughout this dissertation
hereafter, “DM” shall refer to type 2 DM specifically, unless otherwise noted.
Approximately 6% of the world’s adult population is living with DM16 and it is
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recognized as a global health epidemic by the World Health Organization. Additionally,
DM is closely associated with many complications including vascular disease,
retinopathy, nephropathy, and of direct relevance to this dissertation, peripheral
neuropathy16,17.
Diabetic polyneuropathy (DPN) generally refers to nerve dysfunction as a
complication of DM. It is estimated that 50% of patients with DM will develop DPN at
some point in their lives18. In its broadest context, DPN can refer to any of a group of
neuropathic conditions with relatively heterogeneous patterns of neurological
involvement. However, two major subgroups of DPN have been proposed: typical DPN
and atypical DPN19. Atypical DPNs are rarer and can feature acute, sub-acute or chronic
onset of symptoms, with a monophasic or fluctuating course. Additionally, atypical DPNs
often feature burning pain and hyperalgesia to touch, along with minimal sensory loss
and motor dysfunction. In contrast, typical DPN is described as a chronic, symmetrical,
length-dependent sensorimotor polyneuropathy19,20. Typical DPN features sensory (i.e.
numbness and paresthesia) and motor (i.e. atrophy and weakness) dysfunction
progressing in a length-dependent manner19,20. “Length-dependent” refers to the length of
sensory and motor neuron axons, meaning symptoms (i.e. numbness and weakness)
typically manifest first in the feet, progressively moving into the legs and hands; with
continued advancement in a distal to proximal pattern19,21. Epidemiological studies report
typical DPN is the most common form of DPN, as its name indicates19. Throughout this
dissertation, the term DPN shall refer to the typical, sensorimotor form of the disease.

1.3 Pathophysiology of DPN
The precise mechanisms underlying the development of DPN are not entirely
clear21. However, DPN is likely caused by diabetes-related metabolic or vascular
disturbances that are not mutually exclusive, and may be interrelated or synergistic21.
These mechanisms, briefly outlined below, lead to axonal loss via a dying-back, or
retrograde degradation, as well as peripheral nerve demyelination21.
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Vascular disease is a known complication associated with DM22. Indeed
microangiopathy has been shown to develop early in DPN, and these abnormalities may
directly relate to subsequent nerve dysfunction. More specifically, microangiopathy
within the vasa nervorum (which provide the blood supply to peripheral nerves) may
cause nerve dysfunction as a result of ischemic damage. Vasodilation is limited in DM
due to disrupted nitric oxide signaling in blood vessels23. Additionally, DM is associated
with increases in blood viscosity24, impaired oxygen release from blood to tissue25, and
dysfunctional structural alterations of red blood cells26. Thus these combined changes
may contribute to chronic hypoxia and ischemia resulting in nerve damage21. However,
whether microangiopathy and the resultant hypoxia are the primary causes of DPN is the
subject of debate. Whereas some studies have found decreases in nerve blood blow
associated with DPN, others have actually found increases27 or no changes in nerve blood
flow28, despite the clear development of impaired nerve function (see 21 for review). The
reasons for these disparate findings may be related to technical differences in the way
blood flow was measured, as well as key differences in the experimental model or
population studied21.
The other postulated mechanisms underlying DPN are related to a variety of
metabolic and cellular signaling abnormalities that are consequences of DM and chronic
hyperglycemia (see Figure 1.2). Peripheral nerves are especially vulnerable to
hyperglycemic-mediated damage due to their reliance on GLUT-1 and -3 glucose
transporters29,30,31,32. GLUT-1 and -3 transporters are insulin-independent and are
dependent on extracellular blood glucose concentrations. Therefore, under diabetic
conditions (i.e. hyperglycemia and insulin resistance) relatively large quantities of
glucose will be transported into neural tissue. When intraneural glucose concentrations
become too high, several pathways may become active leading to neural dysfunction or
cell death. These cellular processes that may result in damage include: (1) increased
reactive oxidative species (ROS) formation as a result of reverse mitochondrial electron
flow due to excess NAD and FADH accumulation33; (2) excess sorbitol production
leading to cellular osmotic stress34; (3) increased hexosamine pathway activation causing
a chronic inflammatory response35. Additionally, the hyperglycemia-related increase in
advanced glycated end-products (AGEs), caused by the reaction of glucose with various
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fats and proteins, may impose an inflammatory-mediated stressor on neurons 36. Nerve
cell stress in DM may also occur due to the dyslipidemia, for example through oxidized
low density lipoproteins (oxyLDLs) or toxic (i.e. high) concentrations of intracellular fats
which may act through mitochondrial-induced cell death or inappropriate lysosome
activation, respectively37,38. Finally, impairments in nerve cell interaction with various
neurotrophic and growth factors may play a role in the development of neuropathy and
impaired regeneration. Deficiencies in insulin, insulin-like growth factor (IGF), brain
derived growth factor (BDNF), and neurotrophin 3 and 4 (NT3, NT 4) signaling as a
result of diabetes may play a role in the development and progression of DPN39. The
aforementioned postulated mechanisms underlying DPN form a limited list and brief
description that suit the purposes of this dissertation; more comprehensive discussions of
this subject matter can be found elsewhere21,40.
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Figure 1.2 Metabolic mechanisms of nerve damage in diabetic neuropathy
Chronic hyperglycemia and hyperlipidemia in diabetes mellitus may activate multiple
damaging mechanisms in neurons. Note: vascular causes potentially underlying diabetic
neuropathy are not shown. Abbreviations: AGE, advanced glycation end product; GLUT,
glucose transporter; LDL, low density lipoprotein; LDLR, LDL receptor; LOX1,
oxidized LDL receptor 1; oxLDL, oxidized LDL; RAGE, receptor for advanced glycation
end products. Adapted from: Vincent et al 201140
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1.4 Clinical Manifestations of DPN
Confirmed clinical DPN is defined as: “an abnormal nerve conduction study and a
symptom or symptoms or a sign or signs of sensorimotor polyneuropathy” that can be
attributed to DM and no other cause of polyneuropathy19,21. Some of these signs,
symptoms and abnormal nerve conduction studies are described briefly below, and
reviewed elsewhere21.
Patients with DPN typically present with sensory abnormalities, including
numbness, paresthesia, hyperalgesia, or allodynia19. These symptoms usually first appear
in the feet and may advance into the legs, hands and even more proximally over time and
with increasing disease severity19,41. The distribution of sensory symptoms is sometimes
referred to as “stocking and glove”, which reflects the length-dependent progression of
the disease. In clinic, these sensory abnormalities are often assessed through physical
neurological examination, quantitative sensory testing (QST), and Semmes-Weinstein
monofilaments19.
Additionally DPN patients often present with dysfunction of the motor nervous,
or neuromuscular system42,43. The earliest of these signs is usually atrophy of the extensor
digitorum brevis (EDB) muscle in the foot; which may be followed by wasting and
weakness of the ankle dorsiflexors44,45. This muscle weakness may lead to altered gait
and foot posture, as well as other neuromuscular consequences outlined in greater detail
in the next section of this dissertation44. Finally, DPN patients may also display a loss of
reflexes at the ankle or knee17; foot ulceration46; and dysfunction of the autonomic
nervous system, including distal anhidrosis, constipation, impotence, orthostatic
intolerance, among other symptoms47.
Electrophysiological testing is an integral aspect of any clinical assessment of
suspected DPN, and is considered to be the gold standard in DPN evaluation19,21,48. These
measures, namely nerve conduction studies, have been shown to be clinically reliable and
sensitive to the neurological changes associated with DPN. The elicitation of a sural
nerve sensory nerve action potential (SNAP) that has a reduced amplitude (<6 µV) or is
absent when recording from the posterior aspect of the ankle has proven to be the earliest
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electrophysiological sign of DPN51. A prolonged peak sural nerve sensory nerve
conduction latency (>4.9 ms) is another potential electrophysiological sign of DPN49. In
more severe cases of DPN, abnormalities in fibular nerve motor nerve conduction
velocities (MNCV; <40 m/s) or reduced compound muscle action potential (CMAP)
amplitudes from the anterolateral compartment of the leg (i.e. tibialis anterior; <4.0 mV)
are signs of detectable motor involvement49. In addition, other electromyographic-related
measures have been used to evaluate nerve dysfunction in DPN such as motor unit
number estimates (MUNE)50 and neuromuscular transmission stability (i.e. jitter)51 which
will be discussed in further detail in this dissertation (Sections 1.5 and 1.9). Aside from
their clinical relevance the aforementioned electrophysiological measures listed
previously can provide detailed information regarding the status of the sensory and motor
nervous systems in a minimally invasive manner which can prove invaluable in the
context of scientific, physiological investigations.

1.5 Neuromuscular Consequences of DPN
Although early and mild cases of DPN predominantly feature abnormalities of the
sensory nervous system, it is clear stressors associated with DM may target motor
neurons42 and thus DPN can be associated with substantial dysfunction of the
neuromuscular system (see 43 for a brief review).
DPN-related neuromuscular dysfunction may manifest in altered motor neuron
properties including reduced firing rates52, increased firing rate variability52 and motor
neuron excitability changes53. Additionally, animal studies have shown DPN can result in
changes at the muscle-level including disrupted t-tubules54, dysfunctional ion pumps and
channels54–57, and degenerated mitochondria33,54. However, perhaps the most obvious
neuromuscular consequence of DPN is skeletal muscle atrophy and resultant
weakness45,58,59. Loss of isometric strength in the ankle dorsi- and plantar flexors, as well
as knee extensors has been previously reported in DPN patients58,60,61. A primary
mechanism underlying this strength loss is muscle atrophy62. For example, as mentioned
in the previous section, atrophy of EDB is a sensitive and early indicator of DPN63.
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Additionally, magnetic resonance imaging (MRI) has been used to show substantial
muscular atrophy in leg muscles of DPN patients, along with increased fatty infiltration
of muscle64. The same study also reported decreased: plantar flexion strength; isokinetic
power; as well as decreased strength or power per unit of muscle volume (i.e. decreased
muscle quality)64. It remains unknown if the loss of power production is due to strength
loss alone, or if a concomitant loss of muscle contractile velocity also occurs. The DPNrelated decrease in muscle quality could be due to increases in antagonist co-activation,
reductions in myocellular contractile protein expression, disruption in Ca2+ handling, or
intermittent neuromuscular transmission failure.
It is not clear how DPN may affect neuromuscular fatigability. A previous study
investigating type 1 DM found patients actually have greater relative muscular endurance
versus healthy controls61. However, the majority of patients included in that previous
study did not feature substantial motor involvement in their neuropathy and no measures
of voluntary activation were made. In contrast, studies reporting on clinical populations
other than DPN that involve dysfunction of physiological systems in common with DM
and DPN have found increases in fatiguability. For example, it has been shown
previously that individuals with metabolic disease without neuropathy (e.g. type 1 DM)65,
vascular disease (e.g. chronic heart failure)66, or nerve disease (e.g. amyotrophic lateral
sclerosis [ALS])67, fatigue more quickly than controls. Thus it remains to be determined
how neuromuscular fatigue is impacted by DPN.
The neuromuscular consequences described previously can have major impacts,
which are perhaps magnified by deficits in the sensory nervous system, in relation to
functional status and quality of life. Weakness of the dorsi- and plantar flexors is
associated with gait abnormalities and increases in fall risk44,68. Gait abnormalities can
lead to damaged, malfunctioning ankle joints, as well as the development of ulcers46,60,
which are closely associated with lower-limb amputation69. Increased fall risk in DPN
patients is an especially important concern as patients with DM are at greater risk of
injurious falls (e.g. hip fractures) compared to healthy controls70. Finally, these functional
decrements may limit the patient’s ability to actively participate in exercise-based
rehabilitation programs, which are an effective avenue to maintain glycemic control and
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reduce DM-related disease severity71. Since neuromuscular consequences of DPN can
lead to such unfortunate declines in functional ability and quality of life, their study is
important and may lead to enhanced strategies of compensation.

1.6 Motor unit number estimations (MUNE) in humans
In humans, the loss of motor units has been acknowledged as a key physiological
process underlying various neuromuscular diseases72 as well as contributing to functional
declines of the NM system associated with natural adult aging73. Therefore developing
methodologies for quantifying the number of functional motor units in a muscle in vivo
has been of great interest in clinical neurophysiology. Standard electrophysiological
measures such as motor nerve conduction studies (MNCS) and needle electromyography
(EMG) serve as qualitative proxy measures of motor unit numbers; however they are not
sensitive to mild degrees of motor unit loss, particularly following successful collateral
reinnervation that may occur in some diseases and presumed to occur as part of adult
aging72,74.
The concept of the motor unit number estimate (MUNE) was developed to help
address the limitations associated with standard clinical electrophysiological techniques
in quantifying motor unit populations within a muscle. Due largely to improvements in
computer processing capabilities, MUNE techniques have been greatly improved since
their original inception in the 1970s72,74. Although MUNE actually refers to several
different specific electrophysiological methodologies, each MUNE technique is
conceptually similar in that it is based upon the ratio between the maximal compound
muscle action potential (CMAP) divided by the mean surface motor unit potential
(SMUP). The CMAP is representative of the maximal electrophysiological size of the
entire motor unit pool within a muscle, and the mean SMUP is representative of the size
of the average single constitutive motor unit. The primary difference between each
MUNE technique is how the mean SMUP is derived.
Since 1971 when MUNE was first reported75, different techniques have been
developed. Each methodology features various strengths and limitations, and at present
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no single MUNE technique is accepted as the ‘gold standard’72,74. Indeed, no gold
standard exists even pertaining to the physical counting of motor units or motor axons
due to technical limitations in histochemistry. Some common electrophysiological
MUNE techniques include: (1) incremental stimulation, (2) multiple point stimulation,
(3) statistical, (4) motor unit number index (MUNIX) and (5) spike triggered averaging
(STA) with EMG decomposition. These techniques possess various inherent advantages
and limitations which have been previously reviewed in the literature72,74 and, aside from
the STA with EMG decomposition technique, will not be discussed within the confines of
this thesis.

1.7 Spike triggered averaging (STA) and STA with decomposition-based
quantitative electromyography (DQEMG) MUNE
Spike triggered averaging (STA) MUNE combines simultaneous collection of
needle and surface EMG in a given muscle during voluntary contractions76. During a
low-level voluntary contraction, the EMG operator positions the needle electrode so that
only the single motor unit of interest is being recorded. This needle-detected motor unit
potential (MUP) is then used as a trigger to time lock the response from the same motor
unit being recorded at the surface electrode. This process is repeated until sufficient
(approximately 20) single surface motor unit potentials (SMUP) have been recorded to
provide a representative mean76. The mean SMUP is then divided into the maximal
CMAP to provide a MUNE, similar to other techniques. This technique has been
improved upon with the inclusion of EMG decomposition software which allows for
decomposition-enhanced STA (DE-STA). DE-STA MUNE is based upon the same
premise as traditional STA MUNE, however it is much more efficient and allows the
investigator to sample from a wider range of the motor unit recruitment profile of a
muscle77–79. This means DE-STA can record motor units that are recruited at higher
intensities compared to traditional STA, which is generally limited to recording lowthreshold motor units. Thus DE-STA may provide a more representative sample of motor
unit size compared to STA without decomposition. DE-STA involves the application of
decomposition algorithms to the EMG interference pattern, allowing the software to
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decompose the signal into its individual, constituent MUP trains (MUPTs)77. This allows
a greater number of individual motor units to be sampled simultaneously, during higher
intensity contractions. Another advantage of this MUNE technique is that it allows for the
collection of needle EMG data that may provide other useful information regarding the
physiological status of the neuromuscular system including: motor unit firing rates,
neuromuscular transmission stability (i.e. jitter and jiggle), and transmission failure (via
% blocking). A common software used to perform DE-STA is decomposition based
quantitative EMG (DQEMG)77,79,80, which will be described in greater detail in a
subsequent section (Section 1.9).

1.8 Clinical usage of MUNE
The MUNE methods previously outlined have been applied in various clinical
models of human neurological or neuromuscular disease. ALS has been a frequent target
for the application of MUNEs given this disease involves directly large and rapid loss of
motor neurons81,82,83. In the United States, the Food and Drug Administration (FDA) has
not yet accepted MUNE as a primary endpoint measure in ALS clinical trials because the
clinical meaning of MUNE has not been sufficiently established84. However, MUNE
results in ALS clinical trials have been corroborated by other standard clinical
measures82. Moreover, in ALS, MUNE has proven to be more sensitive than strength
testing in predicting the onset of ALS-associated symptoms85. Beyond ALS, MUNE has
been used to detect motor unit losses in spinal muscle atrophy86, Charcot Marie Tooth
neuropathy87, stroke-related hemiparetic muscle88 and, most relevant to this dissertation,
diabetic polyneuropathy50. Additionally, MUNE techniques have been used multiple
times in the literature to examine how the neuromuscular system changes with adult
aging73,89,90.
The lone previous study using MUNE more than 35 years ago in human diabetic
neuropathy found significantly fewer motor units in DPN patients compared with agematched controls in the extensor digitorum brevis (EDB) muscle50. EDB was likely
selected for study due to its known involvement in DPN, especially given the length-
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dependent progression of the disease. MUNE results in DPN patients were positively
correlated with a decrease in motor nerve conduction velocities, a standard measure of
neuromuscular dysfunction associated with DPN. Additionally, Hansen and Ballantyne50
reported MUNEs were negatively related to: age, duration of diabetes and MUP size.
This study helped establish the potential clinical utility of MUNE in examining patients
with DPN, and was the first to electrophysiologically show DPN was related to a loss of
motor units. However, studying EDB in the context of MUNEs and DPN has important
limitations. The functional status (e.g. strength) of EDB is difficult to assess; moreover
EDB has relatively limited functional importance in day-to-day activities of living
compared to other limb muscles. Additionally, when examining EDB it may be difficult
to definitely attribute motor unit loss to the neuronal impacts of diabetes per se, or
mechanical damage induced via altered gait and sensory and proprioception dysfunctions.
Furthermore, in DPN, it remains unclear how data acquired via MUNE may integrate
with other complementary measures (i.e. muscle strength, muscle morphology) in
providing comprehensive information regarding the impacts of DPN on the
neuromuscular system in humans.

1.9 Decomposition-based quantitative electromyography (DQEMG)
Quantitative assessment of motor unit action potentials (MUAPs) from individual
motor units can provide useful and interesting information for the physiological appraisal
of the neuromuscular system. One method that is used to accomplish this assessment is
through using the computer software decomposition-based quantitative EMG
(DQEMG)78,91,92. DQEMG software combines intramuscular EMG and surface EMG
with a series of algorithms that can decompose a complex EMG pattern into its
individual, constituent motor unit action potential trains (MUAPTs)77,78. Subsequently,
DQEMG software provides more detailed information for each MUAPT including: firing
rate, firing rate variability, size, shape, and stability. Additionally, DQEMG can be used
to derive a MUNE via the DE-STA method, as described previously (Section 1.7)78,79,93.
Further details regarding DQEMG are subsequently presented.
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DQEMG typically involves the collection of both micro and macro signals92.
Micro signals are derived via intramuscular, needle EMG electrodes which provide
selective, detailed spatial and temporal information regarding individual motor units.
Macro signals are usually collected via surface electrodes which provide information
regarding overall size and spatial distribution of single motor units. Needle EMG data can
be acquired via concentric, monopolar or single fibre needle electrodes during sustained,
isometric voluntary contractions, typically of 30 seconds in duration. For the purposes of
this brief description, discussion will be limited to data acquired via concentric needle
electrode, although the general principles for each needle-type are the same.
The aforementioned micro signal, collected during low to moderate level muscle
contractions, originally consists of a complex EMG interference pattern from multiple
motor units. This EMG pattern is decomposed into its constituent individual MUAPTs
using a series of algorithms which classify and cluster individual MUAPs based on
MUAP shape, firing rate, and firing rate variability. The macro (surface EMG) signal is
analyzed in temporal alignment with the decomposed micro signal. This is performed by
using each individual MUAP as a trigger which locks to a 100 ms epoch of the macro
signal. This method allows for the derivation of surface motor unit potentials (SMUPs),
which correspond to the relative size of individual motor units within a muscle, and are
used to calculate a MUNE as described previously (Section 1.6). MUNEs calculated
using DQEMG software have been reported with high degrees of intra- and inter-rater
reliability79,94. It is noteworthy that contraction intensity has been shown to have a
marked effect on DQEMG-derived MUNEs93,95. Studies performed in the first dorsal
interosseous (FDI)93 and tibialis anterior (TA)73 have found with increasing contraction
intensities, from 10%-50% MVC, mean SMUPs increase resulting in decreased MUNEs.
McNeil et al (2005) concluded, in the TA, a contraction intensity of 25% MVC includes
recruitment of the majority of low- and high-threshold motor units, and thus provides the
most representative MUNE compared to other contraction intensities73.
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1.10 Analysis of individual motor unit action potential trains (MUAPTs)
In addition to providing CMAPs, SMUPs and MUNEs, DQEMG can provide
detailed information regarding the temporal, spatial and morphological characteristics of
individual needle-detected MUPs78,92. Some of these parameters include: MU firing rates,
MU firing rate variability, MUP size (amplitude, area), MUP shape and complexity
(turns, phases), MUP density (fibre count) and MUP stability (jitter, jiggle, % blocking).
Increases in MUP size and complexity are electrophysiological signs of enlarged,
collaterally reinnervated motor units, which are associated with various disease
processes96 as well as adult aging76,97,98. These parameters are commonly included in a
clinical, intramuscular needle EMG assessment. With major involvement of the
neuromuscular system in DPN, abnormal findings indicative of skeletal muscle
denervation have been reported50,51,99.
MUP stability refers to the integrity of neuromuscular transmission, which can be
examined in detail through the assessment of the degree of variability in the shape of
consecutively detected MUPs100. The two key properties related to MUP shape variability
are termed jitter and jiggle100,101. Jitter refers to the variability of the time intervals
between pairs of individual muscle fibre potentials from a single MUP, and jiggle refers
to the variability in overall MUP shape from one MUP discharge to the next (see Figure
4.1). Increases in both jitter and jiggle have been reported under conditions of
neuromuscular transmission disturbance and can reflect early axonal denervation51,102,103.
Specific to DPN, a previous study using single fibre electromyography (SFEMG) found
increased jitter in the tibialis anterior (TA) of patients with DPN, however jiggle was not
reported51. Additionally, increased fibre density (fibre count) in patients with DPN
compared to controls was observed, which is indicative of reinnervation similar to the
interpretation of enlarged, more complicated MUPs51.
A limitation associated with traditional MUP morphological parameters (e.g. size,
complexity) as well as traditional jitter and jiggle, is they can be difficult to assess at
voluntary contraction levels greater than very light (approximately 5-10% of MVC). This
is due to increases in EMG signal intensity and complexity that may lead to
electrophysiological contamination of single MUPT analysis. Thus most clinical needle
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EMG studies are performed at minimal contraction intensities, often using SFEMG. This
constrains most clinical needle EMG assessments to relatively few and exclusively low
threshold motor units, limiting the scope of data obtained. One potential solution to this
issue involves the development of near fibre (NF) MUP parameters that are obtained via
a high-pass filtered MUP template, which therefore focuses on the electrophysiological
contributions of muscle fibres that are nearest (within ~350 µm) to the needle electrode
centre of detection104. Filtering the EMG signal in this way reduces contributions from
electrophysiological signals located greater than ~350 µm away from the needle detection
surface, and thus this analysis may prove more robust than traditional MUP analysis,
especially during MUNE protocols which require sustained, moderate level (25% MVC)
contractions. Some NF parameters of interest include: NF count (a measure of fibre
density), NF jiggle (which can be used to assess the neuromuscular transmission
variability of the near fibers), NF dispersion (which measures the temporal dispersion of
the near fiber contributions) and maximum NF interval (which is the maximum time
interval between temporally adjacent near fiber contributions to a NF MUP). At present,
no study has reported these measures in patients with neuropathy therefore their utility
remains poorly understood.
Thus, DQEMG provides a unique and convenient platform to combine MUNE
and needle-detected MUP analysis measures to gain a more detailed understanding of
pathological alterations to the neuromuscular system imposed by DPN. Further study
using DQEMG software is warranted to determine how changes in neuromuscular
transmission stability and neuromuscular remodeling may relate to one another, as well
as other aspects of functional capacity and disease severity in patients with DPN.
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1.11 Purposes and Hypotheses
Broadly stated, the primary purpose of the studies described herein (Chapters 2, 3,
4, 5, & 6) was to investigate the physiological impacts of DPN on the neuromuscular
system in humans. More specific objectives and hypotheses are as follows:

1. Purpose: To determine if the loss of strength reported in patients with DPN is related to
a loss of motor units, as quantified using DQEMG (Chapter 2).
a) It was hypothesized that DPN patients would have fewer motor units
compared to controls, and MUNEs would be positively associated with
strength.
2. Purpose: To determine if a length-dependency exists regarding the DPN-related loss of
motor units in humans (Chapter 3).
a) It was hypothesized that MUNE of the TA would be more greatly
affected by DPN than FDI.
3. Purpose: To determine how DPN affects the stability of neuromuscular transmission
using the electrophysiological parameters jiggle, jitter and percent blocking (Chapter 4).
a) It was hypothesized that patients with DPN would feature a greater
degree of neuromuscular transmission instability (i.e. greater jiggle, jitter
and % blocking) compared to healthy controls.
4. Purpose: To assess the effect of DPN on dorsiflexor muscle contractile properties,
including contractile speed and muscle morphology, in association with DPN-related
denervation (Chapter 5)
a) It was hypothesized DPN patients would have weaker, slower muscles
with greater proportions of non-contractile intramuscular tissue that would
be negatively correlated with MUNE.
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5. Purpose: To examine the neuromuscular fatigability of patients with DPN using
sustained isometric contractions and identify possible mechanisms underlying differences
from controls (Chapter 6).
a) It was hypothesized DPN patients would be relatively more resistant to
fatigue due to slowed muscle properties and the less absolute strength.
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Chapter 2
2

Motor unit loss and weakness in association with diabetic
neuropathy in humans1
2.1 Introduction
The most common form of diabetic neuropathy is a length dependent symmetrical

neuropathy with predominant involvement of sensory fibres1. In more severe forms there
is progressive involvement of motor fibres2. Animal models show that relative to the
sensory nervous system, motor axons are more resistant to the effects of diabetes mellitus
(DM)3. Nonetheless these models indicate motor axons are targeted by DM and undergo
degeneration4. In humans, motor axon or motor unit (MU) loss as a complication of DM
has been quantified in the extensor digitorum brevis (EDB)5. However, in intrinsic foot
muscles such as the EDB it may be difficult to differentiate between axonal loss caused
by physical trauma versus damage caused by biochemical stressors associated with
diabetes. Furthermore, investigating MU loss in more functional muscles (e.g. tibialis
anterior) allows for the assessment of other relevant clinical and physiological properties
such as strength and fatiguability. Thus the purpose of this study was to estimate the
number of functioning MUs in the tibialis anterior, using an electrophysiological method,
in a group of patient with DM in comparison to age and sex matched controls.

1

A version of this chapter has been published. Used with permission from John Wiley
and Sons, Inc.
Allen, M.D., Choi, I.H., Kimpinski, K., Doherty, T.J., Rice, C.L. Motor unit loss and
weakness in association with diabetic neuropathy in humans. Muscle Nerve, 48(2):298300, 2013.
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2.2 Materials and Methods
Participants
Six patients (4 men and 2 women; age, 63 ± 16.1 years) were recruited for this
study. All patients met criteria for the diagnosis of DM and had clinical and
electrophysiological features of confirmed diabetic polyneuropathy (DPN)2. Additionally,
all patients had a thorough history and clinical examination to exclude other causes of
nerve injury (i.e. compressive mononeuropathies or L5-S1 radiculopathies). Six healthy,
age and sex-matched controls (4 men and 2 women; age, 62 ± 16.3 years) were recruited
from the community. The study was approved by the local university’s research ethics
board. Informed, oral and written consent was obtained from all participants prior to
testing.
Motor Unit Number Estimates (MUNE) and Dorsiflexor Strength
To assess dorsiflexion strength, participants were seated in a custom isometric
dynamometer. Surface electromyography (EMG) was collected from the tibialis anterior
using self-adhering Ag-AgCl electrodes. Intramuscular EMG signals were recorded via a
disposable concentric needle electrode inserted into the TA, 5-10 mm proximal to the
active surface electrode.
All EMG data were acquired using customized software on a Neuroscan Comperio
system (Neurosoft, El Paso, TX). The algorithms used for decomposition-based
quantitative EMG (DQEMG) and decomposition-enhanced spike-triggered averaging
(DE-STA) have been described in detail elsewhere6,7. In brief, the surface and
intramuscular EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz,
respectively. Surface electrodes (Marquette Medical Systems, Jupiter, FL) were applied
to the TA muscle using standard methods and the maximum CMAP for the TA muscle
was obtained by supra-maximal stimulation of the fibular nerve, just distal to the fibular
head, with a hand held stimulating electrode. Next, three maximal voluntary dorsiflexion
contractions (MVCs) were performed. Subsequently, participants matched a target line
of 25% MVC for all isometric contractions because this contraction intensity has been
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shown to be the most effective intensity for obtaining a representative motor unit number
estimation (MUNE) in the tibialis anterior (TA)8. Surface and concentric needle (Model
N53153; Teca, Hawthorne, NY) EMG were collected simultaneously while participants
sustained a steady target torque for each contraction for ~30 s. These contractions were
repeated until at least 20 suitable trains of motor unit potentials (MUPs) and their
respective surface-motor unit potentials (S-MUPs) were collected.
Decomposed EMG signals were reviewed off-line to determine the acceptability
of the needle-detected MUP trains and their corresponding S-MUPs. A computer
algorithm aligned the negative onset markers for all accepted S-MUPs and created a
mean S-MUP template based upon their data-point by data-point average. A MUNE was
derived by dividing the negative-peak amplitude of the CMAP by the negative peak
amplitude of the mean S-MUP9.
Torque signals were collected and sampled online at 500 Hz using Spike2
software (Cambridge Electronic Design, Cambridge, UK) and analyzed off-line to
determine voluntary isometric torques (strength).
Statistics
Group CMAP, MUNE and isometric dorsiflexion strength data were compared
using a one way ANOVA. Group mean S-MUP data were not normally distributed, thus
these data were compared using a Kruskal-Wallis one way analysis of variance by ranks.
All data are presented as group means ± standard deviations. Significance was set at p ≤
0.05.

2.3 Results
All results all presented in Table 2.1. Control (n=6) and DPN (n=6) groups were age
and sex matched (p>0.05). DPN patients were found to be ~60% weaker in isometric
dorsiflexion strength (Nm) versus controls (p<0.05). DPN patients possessed
significantly reduced (~40%) CMAP negative peak amplitudes (mV) and enlarged SMUP (~50%) negative peak amplitudes (µV) (p<0.05). These changes resulted in ~60%
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fewer MUs based on MUNE in DPN patients when compared to controls (p<0.05). DPN
patients had mean motor unit firing rates of 10.2 ± 1.5 pulses per second; controls had
mean motor unit firing rates of 12.1 ± 0.9 (p<0.05). During the 25% MVC contractions
DPN patients produced 29.0 ± 3.6% of maximal RMS EMG; controls produced 24.5 ±
6.4% of maximal RMS EMG (p>0.05).
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Measure
Age

Control (6)

DPN Patient (6)

% Difference

62 ± 16.3

63 ± 16.1

1.6%

39.0 ± 10.6

15.9 ± 4.0*

59.3%

TA CMAP NP Amplitude (mV)

6.2 ± 1.3

3.9 ± 0.9*

38.1%

TA S-MUP NP Amplitude (µV)

57 ± 19

109 ± 47*

47.4%

TA MUNE (#)

111 ± 22

45 ± 27*

59.1%

Sural Nerve SNAP Amplitude (µV)

-

1.6 ± 0#

-

Sural Nerve CV (m/s)

-

32.4 ± 0#

-

Fibular Nerve CV (m/s)

-

37.6 ± 5.8

-

Tibial Nerve CMAP Amplitude
(mV)

-

1.6 ± 1.7

-

Tibial Nerve CV (m/s)

-

33.9 ± 2.9

-

Dorsiflexion Strength (Nm)

Nerve Conduction Studies

Table 2.1 Strength and motor unit number estimates of the tibialis anterior in controls
and patients with diabetic polyneuropathy
Nerve conduction study data presented in the patient group are outside of normal ranges.
DPN = diabetic polyneuropathy; Nm = Newton*metre; TA = tibialis anterior; CMAP =
compound muscle action potential; NP = negative peak; mS-MUP = mean surface motor
unit potential; MUNE = motor unit number estimate; SNAP = sensory nerve action
potential; CV = conduction velocity. * denotes significant difference between groups,
p<0.05; # sural nerve responses were absent in all patients except one
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2.4 Discussion
DM imposes unique, chronic forms of damage and degeneration to the peripheral
nervous system. Whilst damage to the sensory nervous system is often observed
clinically, much less is known about the long-term effect of DM on the motor nervous
system. Our results provide new evidence in humans of MU loss with DM, in association
with significant decreases in strength, using DQEMG-derived MUNE.
Using various electrophysiological MUNE techniques, MU loss has been
previously documented in other diseases affecting the nervous system8 and in DM in an
intrinsic foot muscle5. MU loss and associated muscular weakness as a result of DM has
not been directly quantified in the TA in humans despite the inclusion of related clinical
signs such as atrophy, weakness, and reduced CMAPs in the description of patients with
DPN9. Our findings indicate the weakness, muscular atrophy, and increased fatigue
reported in DPN patients may be partially accounted for by a loss of MUs. However,
MUNE does not allow for the differentiation between distal axonal retraction versus
motor neuron death.
In rodent models of chronic experimental diabetes, motor neurons undergo distal,
axonal dropout, whereby motor neurons gradually withdraw their terminals from distal
innervation of their associated muscle3. Additionally it has been suggested that smaller
MUs are preferentially targeted or there is a general enlargement of surviving MUs
through compensatory sprouting3. Our results of pathologically enlarged S-MUPs within
the patient group also indicate an ongoing process of denervation and collateral
reinnervation in DM patients6,10. However, the observation of reduced strength in the DM
group indicate the process of denervation is outpacing collateral reinnervation, leading
not only to a reduction in MUs but also to probable atrophy of muscle tissue and
concomitant loss of strength11.
The TA was selected for investigation in the present study due to the distal to
centripetal progression of diabetic neuropathy12 and its functional relevance in mobility,
balance and association with fall-risk13. Given the pattern of the development of
weakness in patients with diabetic neuropathy it seems likely that MUs would be
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preserved in more proximal limb muscles, such as the quadriceps or biceps brachii,
although this remains to be determined12,14.
The results from the present study indicate DQEMG-derived MUNE may have
some clinical utility in predicting functional impairment, tracking DM progression and
disease management. This may be particularly useful in individuals whose diabetic
neuropathy features a detectable motor component (i.e. muscle wasting, reduced CMAP,
weakness) using standard clinical measures (i.e. manual muscle testing, motor nerve
conduction studies). Additionally, it remains to be determined how MU loss in DM
patients relates to other relevant clinical and functional measures.
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Chapter 3
3

Length dependent loss of motor axons and altered motor unit
properties in human diabetic polyneuropathy2

3.1

Introduction
Diabetic polyneuropathy (DPN) is a generalized disorder of the peripheral

nervous system caused by metabolic and vascular stressors associated with diabetes
mellitus (DM). The pathophysiology underlying this nervous system dysfunction may be
due to a combination of various metabolic and vascular factors1, and is correlated with
disease duration and quality of serum glucose control (e.g. as indicated by HbA1c
levels)2,3. In the early stages of DPN, patients often present with predominant
involvement of the sensory nervous system and no clinical impairment in motor function
is detectable4,5. Regardless of the underlying causes, DPN commonly develops as a
length-dependent, or progressive centripetal degeneration of peripheral nerve axons6.
This manner of disease progression typically leads to development of length dependent
neurological complications first in the feet, followed by the legs and hands.
Although motor neurons may be more resistant than sensory axons to the
dysfunction and degeneration associated with diabetes mellitus7,8,9, studies in animal and
human models nonetheless have shown that the motor system is affected3,10–13. Indeed,
whereas sensory dysfunction can lead to injury resulting from lack of sensation,
ulceration and amputation; dysfunction of the motor nervous system is associated with
muscle atrophy and weakness14,15. Muscle weakness may therefore contribute to the
higher risk of developing physical disability in patients with diabetes16.

2

A version of this chapter has been published. Used with permission from Elsevier, Inc.

Allen, M.D., Kimpinski, K., Doherty, T.J., Rice, C.L. Length dependent loss of motor
axons and altered motor unit properties in human diabetic polyneuropathy. Clin
Neurophysiol 125(4):836-43, 2014.
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Muscular atrophy and weakness associated with DM may be partially a result of
motor unit or motor axon loss. Electrophysiologically-derived motor unit number
estimates (MUNEs) in human patients with DPN have been shown to be significantly
reduced in one distal muscle of the lower limb, specifically an intrinsic foot muscle, the
extensor digitorum brevis (EDB)10 and, in preliminary findings, in the tibialis anterior
(TA)13. In EDB, these pathological changes in motor unit number and properties were
correlated with age and disease duration10. Motor unit loss has been reported concurrent
with significant muscular weakness when compared with age and sex-matched human
controls13. In addition to reduced MUNEs, changes in motor neuron properties have been
reported in patients with DPN. Abnormal single-fiber electromyography recordings
(increased jitter) have been found in DPN patients, suggestive of reinnervation of the
motor system, which correlated with glycemic control3. Also, previous studies indicate
patients with DM show lower mean motor unit discharge rates versus controls and greater
variability in discharge rates of action potential trains during sustained low level
contractions17. These findings may be related to changes in recruitment strategy due to
neuromuscular remodeling and altered excitability of motor units18. However it is not
known how these results may compare to potential changes in motor unit numbers of
more proximal or upper limb muscles, or how they relate more broadly to indicators of
disease severity, such as glycemic control.
Decomposition-based quantitative electromyography (DQEMG) is an
electrophysiological technique based on surface and intramuscular EMG, in conjunction
with dedicated computer algorithms used to decompose complex EMG signals19,20. This
technique can be used to provide reliable MUNEs, as well as other valuable information
concerning motor unit properties in humans, including motor unit size, complexity,
stability, recruitment order, and rate coding strategies21–23. Although this useful technique
has been applied to study various clinical and special populations, including amyotrophic
lateral sclerosis21, compressive neuropathies24, knee osteoarthritis23, and adult aging25 it
has not been fully employed in the investigation of diabetic neuropathy (Chapter 2).
The purpose of the present study was to estimate the number of motor units and
assess their electrophysiological properties in an upper (first dorsal interosseus [FDI])
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and lower limb (TA) muscle of patients with DPN using DQEMG. We sought to compare
how motor unit numbers and their properties were affected by DPN and whether changes
in these properties were related. Additionally, the associations between these different
neuromuscular properties with functional parameters (e.g. strength) and measures of
serum glucose control (e.g. HbA1c levels) were investigated across muscles. We
hypothesized DPN patients would feature significantly reduced MUNEs, and enlarged
motor units in both TA and FDI when compared with age matched controls. Additionally,
we hypothesized these differences would be more pronounced in the TA versus the FDI
due to the centripetal nature of DPN disease progression. Finally, we hypothesized
negative relationships would exist between MUNEs and parameters of disease severity.

3.2 Methods
3.2.1

Participants
Twelve patients (7 men, 5 women; ages 32-78 years) with DPN were recruited.

They met the criteria for diagnosis of type 2 non-insulin dependent DM with clinical and
electrophysiological features of confirmed DPN8. Additionally, they had a thorough
history, and clinical and electrophysiological examination by an experienced neurologist
with specialized training in neuromuscular disease to exclude other causes of nerve injury
(i.e., other polyneuropathies, compressive mononeuropathies, radiculopathies). Patients
with any neurological, metabolic or vascular diseases other than related to DM or DPN
were excluded. Twelve healthy, age and sex-matched controls (7 men, 5 women; ages 2977 years) were recruited from the community. Control participants were screened by
physicians (neurologists) to ensure they met inclusion criteria. The study was approved
by the local university research ethics board. Informed oral and written consent was
obtained from all participants prior to testing.
3.2.2

DQEMG and Strength Assessment of Tibialis Anterior
Participants were seated in a custom isometric dynamometer designed to measure

plantar and dorsiflexion at the ankle joint26. In the dynamometer, the right ankle was
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positioned at 30° of plantar flexion, with both knee and hip angles maintained at 90°. A
C-shaped brace was secured directly on the distal aspect of the right thigh to minimize
movement at the hip joint during contractions. Inelastic Velcro straps were placed over
the dorsum of the foot to secure the foot to the dynamometer22.
All testing was performed on the right (dominant) leg. Participants performed
three dorsiflexion maximal voluntary contractions (MVCs), with at least 3 min of rest
between attempts. Each MVC was held for approximately 3 seconds. Participants were
provided with real time visual feedback of their torque and verbally encouraged.
Voluntary activation during the 2nd and 3rd MVC attempts was assessed using the
interpolated twitch technique27. This technique involves supramaximal percutaneous
electrical stimulation of the fibular nerve just distal to the fibular head. The amplitude of
the interpolated torque electrically evoked from a single 100us stimulus during the
plateau of the MVC was compared with a single (100μs) resting twitch evoked ~1s
following the MVC. Voluntary activation was calculated as a percent using the following
equation: [1- (interpolated twitch /resting twitch)] x 100. The peak torque of the three
MVC attempts was taken as the maximal torque for the participant. All torque signals
were collected and sampled online at 500 Hz using Spike2 software (Version 7.11;
Cambridge Electronic Design Ltd., Cambridge, United Kingdom) and analyzed off-line
to determine voluntary isometric torques (strength).
Surface electromyography (EMG) was collected from the TA using self-adhering
Ag-AgCl electrodes (1 cm x 3 cm). The active electrode was placed over the TA motor
point, approximately 7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior
border of the tibia. This placement was adjusted to maximize the TA compound muscle
action potential (CMAP) amplitude as necessary. The reference electrode was placed
over the distal tendon of the TA. A ground electrode was placed over the patella.
Decomposition-based quantitative electromyography (DQEMG) data were
acquired using decomposition enhanced spike triggered averaging (DE-STA) software,
described in detail elsewhere19,28. Intramuscular EMG signals were recorded via a
disposable concentric needle electrode (Model N53153; Teca Corp., Hawthorne, NY)
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inserted into the TA, 5-10 mm distal to the active surface electrode. The surface and
intramuscular EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz,
respectively. Surface EMG was sampled at 3 kHz; intramuscular EMG was sampled at 30
kHz. To evoke the maximum CMAP a bar electrode held distal to the fibular head
delivered supramaximal electrical stimuli to the common fibular nerve. Subsequently,
participants matched a target line of 25% MVC, visible on a computer monitor, for all
isometric dorsiflexion contractions during which the intramuscular needle electrode was
inserted and manipulated in the muscle. This contraction intensity has been shown to be
the most effective intensity for obtaining a representative motor unit number estimation
(MUNE) in the tibialis anterior (TA)22. Surface and intramuscular EMG were collected
while participants sustained a steady target torque for each contraction held for ~30 s.
Between contractions, the concentric needle electrode was repositioned in order to obtain
to sample from different motor units. These procedures were repeated until at least 20
suitable trains of motor unit potentials (MUPs) and their respective surface-motor unit
potentials (S-MUPs) were collected.
Decomposed EMG signals were reviewed off-line to determine the acceptability
of the needle-detected MUP trains and their corresponding S-MUPs. A computer
algorithm aligned the negative onset markers for all accepted S-MUPs and created a
mean S-MUP template based upon their data-point by data-point average. All MUP and
S-MUP markers were subsequently reviewed visually by the operator. A MUNE was
derived by dividing the negative-peak amplitude of the CMAP by the negative peak
amplitude of the mean S-MUP29.
In addition to providing MUNEs, the DQEMG software measures firing rates
(Hz) of individual motor unit action potential trains (MUAPTs), and provides overall
mean firing rates per participant at a relative target level of contraction. Finally, the
DQEMG system allows for the measurement of properties of needle detected-MUPs,
including MUP amplitude, area, duration, and area to amplitude ratio (AAR). The
calculation of the MU size index (SI [SI = 2 x log(amp) + area/amp]), a stable measure
useful in the detection of neurogenic processes, was also performed30. All markers were
automatically placed by the DQEMG software and were subsequently inspected manually

43

and adjusted where appropriate. The DQEMG technique described has been shown to
possess similar test-retest values within individuals31, and high degrees of intra- and
inter-rater reliability in control and clinical populations32,33.
3.2.3

DQEMG of First Dorsal Interosseus
For the FDI, participants were seated in a straight-back chair with their feet on the

floor. The participant’s forearm and hand were secured in a custom-built apparatus
designed to isolate the second (index) digit during isometric abduction contractions34.
This apparatus was designed to minimize any movement in the wrist and hand, while
allowing for isolated index finger abduction (FDI contraction) through the
immobilization of the wrist, thumb and digits three to five with Velcro straps. Torque
data was not recorded for the FDI.
Surface EMG was collected using self-adhering Ag-AgCl electrodes (1 cm by 2.5
cm); the active electrode was placed over the motor point of the FDI muscle and the
reference electrode was placed over the second metacarpal phalangeal joint. A ground
electrode was applied to the medial aspect of the wrist, distal to the stimulation site. To
obtain a maximal FDI CMAP supramaximal stimulation was applied to the ulnar nerve at
the wrist (~7 cm proximal to the active electrode).
Participants performed three index finger abduction maximal voluntary
contractions (MVCs), with at least 3 min of rest between attempts. Each MVC was held
for approximately 3 seconds during which the participant was verbally encouraged.
Visual and auditory feedback were provided to the participant via surface EMG activity,
and maximal RMS EMG activity was recorded during these MVCs. The intensity of
subsequent contractions was based on a percentage (25%) of relative maximal RMS
activity (% MVC-RMS)28,29.
DQEMG data were acquired from the FDI using similar equipment, filter and
amplification parameters to the protocol in the TA (described above). The concentric
needle electrode was inserted into the FDI 2-5 mm distal or proximal to the active
electrode. Participants performed ~30 s FDI contractions, while matching a target line of
25% MVC-RMS, during which surface and intramuscular EMG were collected. These
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procedures were repeated until at least 20 suitable trains of MUPs and their respective SMUPs were collected. Decomposed EMG signals of the FDI were analyzed using the
same methodology used in the TA (described above).
3.2.4

Statistics
Mean values ± standard deviations are presented in the text. Normally distributed

data were analyzed using a one-way ANOVA; the level of significance was set at P ≤
0.05. When a significant main effect was detected, Tukey’s post-hoc test was performed.
Non-normally distributed data were analyzed using a Kruskal-Wallis one-way ANOVA
on ranks, with Dunn’s Method used as the post-hoc test. Effect sizes for comparisons
between groups are presented as Cohen’s d. Relationships between variables were testing
using Pearson’s Product Moment Correlation. Data analyses were performed using
SigmaPlot software (Version 12.2; Systat Software, Chicago, Illinois, US).

3.3 Results
3.3.1

Participant Characteristics
Participant characteristics are presented in Table 3.1. No significant differences

were detected for age or height (p>0.05) between groups. DPN patients had significantly
greater body mass (p<0.05) and BMI (p<0.05) than controls. Maximum ankle
dorsiflexion strength was 40% lower in the DPN group versus controls (p<0.05), with no
group differences for voluntary activation (p>0.05). Data characterizing the clinical
history and status of the DPN patient group are presented in Table 3.2. In both groups,
mean TA and FDI CMAP amplitudes were above our clinic’s lower limit of normal35,
which are 4.0 mV and 10 mV, respectively.
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Control (n = 12)

DPN Patient (n = 12)

Anthropometric Parameters
Male/Female
Age (years)
Height (m)
Weight (kg)
BMI (kg/m2)

7/5
63.8 ± 15.5
1.8 ± 0.1
73.8 ± 6.1
24.4 ± 3.1

7/5
65.8 ± 15.4
1.7 ± 0.1
83.1 ± 7.4*
28.9 ± 3.7*

Dorsiflexion Properties
Dorsiflexion MVC (Nm)
Voluntary Activation (%)

34.1 ± 9.5
98.3 ± 1.9

22.3 ± 7.2*
97.6 ± 2.1

Table 3.1 Participant Characteristics
MVC – maximal voluntary contraction. * Denotes significant difference between groups
(p<0.05).
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Diabetic Characteristics
Duration of Diabetes (years)
Duration of DPN (years)
HbA1c (%)
Triglycerides (mmol/L)
Cholesterol (mmol/L)
HDL Cholesterol (mmol/L)
LDL Cholesterol (mmol/L)
Total Cholesterol:HDL Ratio
Nerve Conduction Studies
Sural Nerve SNAP Amplitude
(µV)
TA NP CMAP amplitude (mV)
Fibular nerve CV (m/s)
FDI CMAP amplitude (mV)
Ulnar nerve CV (m/s)

Range or Limit of
Normal

DPN Patients

<6.0
0.77-1.7
3.0-5.0
0.9-2.0
2.0-3.0
<5.0

14.1 ± 11.2
9.2 ± 8.1
7.4 ± 1.4
1.9 ± 1.3
4.1 ± 0.3
1.3 ± 0.5
2.1 ± 0.8
3.9 ± 0.9

>5

1.3 ± 2.5#

>4.0
>40.0
>10.0
>53.0

5.0 ± 1.7
41.4 ± 10.4
10.3 ± 2.7
49.2 ± 3.4

Table 3.2 Clinical characteristics of DPN patient group
SNAP – sensory nerve action potential; TA – tibialis anterior; NP - negative peak; CMAP
– compound muscle action potential; CV – conduction velocity; FDI – first dorsal
interosseous. # SNAP responses were absent in 10 out of 12 patients.

3.3.2

Decomposition-based Quantitative Electromyography Measures
Results from DQEMG of the TA and FDI are presented in Tables 3.3 & 3.4. In

both muscles, DPN patients featured ~25% greater duration for mean needle-detected
motor unit potentials (NMUPs) than controls (p<0.05), however, mean NMUP amplitude
(peak-to-peak amplitude) and area to amplitude ratios (AAR) were not different between
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groups (p>0.05). In examining NMUP complexity, groups did not differ in the number of
phases (p>0.05), although the DPN patient group featured ~25% more turns than controls
in both muscles (p<0.05). In the TA and FDI, the DPN patient group had lower mean
firing rates during the sustained, submaximal contractions compared to controls (p<0.05).
Motor unit size index and % RMS EMG were not different between groups in either
muscle (p>0.05).
When examining the TA, DPN patients were found to have ~40% larger mean
surface motor unit potentials (S-MUP) than controls (p<0.05). Maximal compound
muscle action potentials (CMAP) (negative peak-amplitude) were significantly smaller
(~30%) in DPN patients compared to controls (p<0.05). Additionally, the DPN patient
group featured a ~45% lower MUNE compared to the control group (p<0.05) (Figure
3.1).
In the FDI, SMUP amplitudes were not different between groups (p>0.05).
Maximal CMAP (negative peak-amplitude) were significantly smaller (~20%) in DPN
patients compared to controls (p<0.05). Finally, the DPN patient group featured a ~30%
lower MUNE compared to the control group (p<0.05) (Figure 3.1). In both TA and FDI,
individual MUNE data for DPN patients and controls are illustrated in Figure 3.2.
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Control

DPN Patient

Effect Size

803.0 ± 145.0

1056.0 ± 468.0

0.88

8.4 ± 1.54
1.6 ± 0.3
2.9 ± 0.2
3.3 ± 0.6

10.8 ± 1.6*
1.7 ± 0.3
3.1 ± 0.3
4.1 ± 0.7*

1.72
0.32
0.62
0.91

77.0 ± 20.0

116.0 ± 61.0*

0.98

Other
Mean Firing Rate (Hz)
% RMS EMG
Motor Unit Size Index

12.2 ± 1.7
20.7 ± 6.1
1.3 ± 0.3

10.1 ± 1.2*
23.3 ± 4.3
1.5 ± 0.6

1.34
1.02
0.71

MUNE
CMAP (mV)
SMUP (µV)
MUNE (#)

6.8 ± 1.1
77.0 ± 20.0
99.0 ± 19.0

5.0 ± 1.7*
116.0 ± 61.0*
54.0 ± 25.0*

2.12
0.98
2.40

N-MUP Parameters
Peak-to-peak voltage
(µV)
Duration (ms)
AAR (ms)
Phases (#)
Turns (#)
S-MUP Parameters
Negative peak
amplitude (µV)

Table 3.3 Decomposition-based quantitative electromyography of tibialis anterior
N-MUP – needle detected motor unit potential; AAR – area to amplitude ratio; RMS
EMG – root mean squared electromyography; CMAP – compound muscle action
potential; SMUP – surface detected motor unit potential; MUNE – motor unit number
estimation. Effect size presented as Cohen’s D. CMAP and SMUP data are presented as
negative peak amplitudes. * Denotes significant difference between groups (p<0.05).
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N-MUP Parameters
Peak-to-peak voltage
(µV)
Duration (ms)
AAR (ms)
Phases (#)
Turns (#)
S-MUP Parameters
Negative peak
amplitude (µV)
Other
Mean Firing Rate (Hz)
% RMS EMG
Motor Unit Size Index
MUNE
CMAP
SMUP
MUNE

Control

DPN Patient

Effect Size

839.0 ± 124.0

846.0 ± 218.0

0.23

8.0 ± 0.74
1.5 ± 0.2
2.7 ± 0.2
2.6 ± 0.2

9.9 ± 1.6*
1.6 ± 0.2
2.8 ± 0.2
3.4 ± 0.5*

2.04
0.17
0.63
1.67

133.0 ± 30.0

157.0 ± 54.0

0.24

14.8 ± 2.2
20.7 ± 1.6
0.9 ± 0.3

12.4 ± 1.9
22.6 ± 3.32
1.1 ± 0.5

1.03
1.17
0.29

12.7 ± 1.6
133.0 ± 30.0
107.0 ± 33.0

10.3 ± 2.7*
157.0 ± 54.0
73.0 ± 18.0*

1.07
0.24
0.96

Table 3.4 Decomposition-based quantitative electromyography of first dorsal
interosseous
N-MUP – needle detected motor unit potential; AAR – area to amplitude ratio; RMS
EMG – root mean squared electromyography; CMAP – compound muscle action
potential; SMUP – surface detected motor unit potential; MUNE – motor unit number
estimation. Effect size presented as Cohen’s D. CMAP and SMUP data are presented as
negative peak amplitudes. * Denotes significant difference between groups (p<0.05).
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Figure 3.1 Comparison of relative differences between DPN patients and controls in key
electrophysiological variables between tibialis anterior (TA) and first dorsal interosseous
(FDI). All relative differences between DPN patients and controls were significant,
excluding FDI mSMUP.
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Figure 3.2 Motor unit number estimates in diabetic neuropathy
Motor unit number estimates in the tibialis anterior (panel A) and first dorsal interosseous
(panel B) in DPN patients and age-matched controls. Group means are represented by
enlarged symbols and feature standard deviation error bars.
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Figure 3.3 Relationship between muscle action potential size and motor unit number estimates
Relationship between compound muscle action potential (CMAP) amplitude and motor unit number estimates (MUNEs) in the tibialis
anterior of DPN patients (black squares) and controls (grey circles). Dotted line represents lower limit of normal (4.0 mV) for CMAP
amplitude. Group means are represented by enlarged symbols and feature standard deviation error bars.
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3.3.3

Tibialis Anterior versus First Dorsal Interosseus Motor Unit Properties
In patients with DPN, the TA has undergone greater motor unit loss in

comparison to the FDI (see effect sizes in Tables 3.3, 3.4). Patients with DPN featured a
~45% lower MUNE in the TA, versus a ~30% lower MUNE in FDI. CMAPs were ~30%
smaller in the TA versus ~20% smaller in FDI. Furthermore, in the TA, DPN patients
were found to have mean SMUPs enlarged by ~40% whereas in FDI there were no
differences.
3.3.4

Disease Severity, Age, Strength and Motor Unit Number Estimates
Within the DPN patient group, in either muscle, no significant relationships were

found between MUNEs and: HbA1c levels, blood lipid profiles, duration of DM, duration
of DPN, or age (p>0.05). TA MUNE and dorsiflexion strength were found to be
positively related to one another (r = 0.79; r2 = 0.62; p<0.05) within the DPN group.

3.4 Discussion
This study has demonstrated that patients with DPN have fewer motor axons,
which may be related to a loss of MUs, in both distal lower (TA) and upper limb (FDI)
muscles compared to healthy, age-matched controls. Neuromuscular properties of the TA
were more severely affected by DPN than FDI in terms of degree of motor unit loss and
motor unit remodeling. The number of motor units in the TA was found to be
significantly positively related to dorsiflexion strength in the DPN patient group. Using
DQEMG, patients with DPN were found to have more complex motor units and lower
mean motor unit firing rates compared to controls at similar levels of contractile intensity.
Finally, in the DPN group, no significant relationships were found between motor unit
loss and disease severity, disease duration or age in either muscle.
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3.4.1

DPN-Related Motor Axon Loss and DQEMG-Derived MUNE
In the present study, the observed motor axon loss associated with DPN in the TA

and FDI is consistent with findings previously reported in extensor digitorum brevis10,
and preliminary findings reported in the TA of a small group of DPN patients13. The
reduced MUNEs in DPN patients are likely primarily due to distal axonal retraction of
motor neurons from their associated muscle fibres and concurrent inadequacy of
compensatory collateral reinnervation, rather than cell death of motor neurons at the
perikaryal level7. Using a rodent model of experimental diabetes, it has been found that
although motor neurons are resistant to immutable loss, indeed, they gradually withdraw
their terminals from distal innervation of skeletal muscle7. A key difference between the
present study and the report by Hansen and Ballantyne10 is that they used a modified
version of the incremental MUNE technique, whereas we have employed DE-STA. The
results from the incremental technique can be affected by several important factors
including the effects of ‘alternation’; the instability caused by neuropathy; and the
assumption that MUs electrically stimulated at low intensities are representative of the
entire MU pool36, which may overestimate the total number of functioning motor units.
DQEMG-derived MUNE accounts for these limitations through its use of voluntary
contractions and algorithms designed to compensate for neuromuscular instability in
detecting single MUPs19. Additionally, at 25% of maximal contractile intensity, the
majority of MUs are recruited in both FDI and TA37,38. Also, the MUNE technique in the
present study has the added benefit of providing data pertaining to needle detectedMUPs19. Although all subjects tolerated the needle component of the assessment very
well, the reliance on needle-electrode insertion with this technique may be uncomfortable
for some DPN patients, especially those with symptoms of painful diabetic neuropathy. It
is also important to note this MUNE protocol has been shown to have high degrees of
intra- and inter-rater reliability32,33, and produces similar test-retest values within
subjects, thus supporting its potential utility in following patients longitudinally31,39.
Finally, it should be noted that DQEMG-derived MUNE is especially useful for studying
more proximal muscles (e.g. TA, soleus, trapezius) versus some other MUNE
techniques13,33,40.
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In addition to technical differences noted above, there are functional differences
between the TA and EDB that may limit a direct comparison. In older adults, it is not
uncommon to observe reduced CMAP amplitudes in fibular motor nerve conduction
when recording from EDB, but not from the TA of the same individuals. As an intrinsic
muscle on the dorsum of the foot, the EDB may be more susceptible to lifelong
mechanical damage regardless of DM, but unlike the TA, relevant functional
impairments of the EDB may not affect important lower limb functions related to
locomotion, postural stability and the risk of falls41.
3.4.2

Length-Dependent Motor Axon Loss in DPN
The degree of motor unit loss in EDB, TA and FDI is variable and the observed

pattern appears to reflect the length-dependent nature of DPN disease progression. In
EDB, a more distally located muscle than FDI or TA, a previous study reported ~63%
fewer motor units in DPN patients compared to controls10. In comparison, the present
study found reduced MUNEs in DPN patients of ~50% and ~30% in the TA and FDI
respectively (Figure 3.1). In this context, interpretation of our results with the prior study
must be done with caution because the DPN patients studied by Hansen and Ballantyne10
featured a shorter mean duration of DM compared to the present study (11.7 vs 16.1
years). Assuming that for any patient a greater loss of motor units occurs with longer
disease duration, it seems plausible the greater relative loss of motor units in EDB is a
reflection of the pattern (peripheral to central) of disease progression rather than an
artifact of inherent differences between DPN patient populations, or due to different
MUNE techniques as mentioned above. Furthermore, greater differences in other
electrophysiological parameters, including maximal CMAP amplitudes and mean SMUP
amplitudes, in the TA versus the FDI fits the general pattern of DPN progression.
These findings highlight that in human DPN, reductions in axonal loss and
presumably motor unit numbers follow the same length-dependent pattern of progression
as other clinical signs and symptoms (i.e. sensory abnormalities, weakness, muscle
atrophy, autonomic dysfunction)1,8. Furthermore, the significant and strong positive
relationship42 between TA MUNE and dorsiflexion strength (r = 0.79) may indicate that a
loss of MUs is an important factor in dorsiflexor weakness. In human adult aging, loss of
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motor neurons has been purported as an important but often overlooked factor related to
muscle atrophy and associated loss of strength (i.e. sarcopenia)43,44. Since innervation is
necessary for the maintenance of muscle mass, and thus strength, it seems likely the
motor unit loss reported in DPN patients in the present study is a key factor leading to the
concomitant loss of strength. Indeed, previous studies have noted a positive relationship
between MUNEs and strength in clinical and special populations including post-polio
syndrome45, amyotrophic lateral sclerosis46, Charcot-Marie-Tooth disease47 and adult
aging25. Additionally, in a rodent model of DPN, motor unit loss has been documented in
the early stages of DPN prior to the manifestation of standard electrophysiological,
behavioral or clinical signs including strength loss12. As weakness of the TA is associated
with increased postural instability and greater likelihood of injurious falls41, early
detection of motor unit loss in DPN patients could prove useful in the prescription and
adoption of preventative or compensatory interventions (e.g. aggressive glycemic control,
strength training, pharmacological interventions).
In addition to motor axon loss, the present study provides indirect evidence of
neuromuscular remodeling and collateral reinnervation via significantly greater needledetected MUP durations; greater MUP complexity (i.e. turns), and greater mean SMUP
amplitudes in the TA of DPN patients compared to controls25 (Tables 3.3 and 3.4). These
findings in the TA of DPN patients may reflect the ongoing process of distal, axonal loss
of α-motor neurons resulting in denervation of their muscles fibres, and compensatory
collateral reinnervation of those orphaned muscle fibres by neighboring α-motor neurons
that remain intact and functional. This process has been documented in animal models of
DM following nerve crush injury48, and leads to the development of larger, more
complex individual motor units, a result that is detectable via MUPs with more turns and
larger average SMUPs. In early DPN, this process may preserve muscle fibres and
maximal CMAP amplitudes48. This result stands in contrast to our findings in the FDI in
which no differences were found in mean SMUP size between DPN patients and controls.
This may be due to FDI undergoing a lesser degree of neuromuscular remodeling and
collateral reinnervation as TA in the DPN patient group as indicated by less substantial
losses in MU numbers.
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3.4.3

DQEMG Compared to Standard Electrodiagnostics
The mean CMAPs in the TA (5.0 mV) and FDI (10.3 mV) of the DPN patient

groups were greater than the lower limits of normal used in our EMG clinic (4.0 mV and
10 mV, respectively)35. Based on this electrodiagnostic criterion alone, as a group, the
DPN patients would not be considered to have undergone significant motor axonal loss
(Figure 3.3). At this time, no standardized lower limits of normal exist for TA and FDI
MUNEs. However, DPN patients featured substantially fewer MUs versus controls, and
these differences were greater than the differences reported in CMAP amplitudes,
particularly in the TA (ΔTA: MUNE ~45%, CMAP ~30%; ΔFDI MUNE ~30%, CMAP
ΔFDI ~20%). Given MUNE takes into account the process of neuromuscular remodeling
and collateral reinnervation via the mean SMUP, MUNE may provide a more sensitive
measure of motor unit loss in comparison to nerve conduction studies alone. In addition,
standard needle EMG studies would also be insensitive to this extent of axonal loss.
Whereas clear differences were found in MUNEs between groups, differences in some
needle detected MUP parameters, such as AAR, size index and number of phases, were
not apparent (Tables 3.3 and 3.4). Thus, our results support the potential inclusion of
MUNE as a useful tool in identifying patients in the early stages of motor-involved DPN,
allowing for earlier detection and intervention.
In addition to motor axon loss and neuromuscular remodelling, our findings
illustrate a decrease (~15% ) in motor unit firing rates in DPN patients compared to
controls at similar contractile intensities (approximately 25%MVC). This result
corroborates a similar finding in the vastus lateralis of type 2 DM patients during low
intensity, ramped knee extension contractions17. They attributed this finding of
neurophysiological adaptation to a slowing of inherent muscle contractile properties
which has been reported in diabetic rodent skeletal muscle49. Additionally, the decreased
firing rates observed in DPN patients may reflect changes in intrinsic properties of αmotor neurons related to excitability. In humans, excitability increases in motor neurons
as a result of Na+/K+ pump dysfunction were reported to be associated with DPN50. This
could result in changes in recruitment patterns, specifically a greater reliance on
recruitment of additional motor units, rather than firing rate increases, as a means of
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grading force output. Furthermore, given the enlargement of motor units found in the TA
of DPN patients, presumably fewer motor units would be necessary at lower relative
firing rates to produce a similar relative level of force output. Our results support this
notion given the lower recruitment and firing rate indices (Tables 3.3 and 3.4) found in
both TA and FDI of DPN patients compared to controls.
3.4.4

Motor Axon Loss and Disease Severity
We did not find any significant relationships between MUNEs and disease

duration or disease severity of DM (e.g. HbA1c levels). This is most likely due to the
modest sample size of the present study and a result of the complex interaction of the
various factors that could drive axonal and MU losses observed in this sample of patients.
In insulin-dependent DM , HbA1c levels have been identified as one of the strongest
predictors of the development and severity of other signs and symptoms (e.g. numbness,
electrophysiological measures) associated with DPN, and therefore the lack of
relationship between MUNE and HbA1c levels is somewhat surprising2,3. Previous
reports featuring substantially larger sample sizes have found significant relationships
between motor dysfunction and neuromuscular remodeling with glycemic control2,3.
Specifically, Bril and colleagues3 found a positive relationship between increased singlefibre EMG jitter, a marker of neuromuscular remodeling, and glycemic control.
Additionally, significant negative relationships between DM disease duration and
MUNE, as well as age and MUNE has been reported; however they did not examine the
role of disease severity, as marked by hyperglycemia or dyslipidemia, in motor unit
loss10. Furthermore, it is important to note HbA1c values recorded at the time of
inclusion in this study only reflect glycemic control for approximately the previous six
months. Thus the patient’s history beyond this six month window is unaccounted for
which could pervasively influence neuromuscular integrity. Additionally, some recent
reports suggest that glycemic control in type 2 diabetics may be less important than
vascular factors in relation to the development and severity of DPN51,52. Conceivably, the
duration of diabetes10, the severity of diabetes, genetic predisposition, age25 and physical
activity patterns53 could all affect MUNE in DPN patients.
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3.4.5

Conclusions
Regardless of these potential relationships, our study demonstrates significant

reduction of MUNE in the TA and FDI in association with DPN. The magnitude of motor
unit loss appears to be muscle dependent, and follows a length-dependent pattern.
Needle-detected motor unit properties are also altered in DPN patients, specifically mean
firing rates and MUP turns. Finally, our study may lend support to the use of DQEMG as
a potential measure that is sensitive to changes not detected by standard nerve conduction
studies associated with DPN. The DQEMG-derived MUNE technique described in the
present study is particularly useful in studying more proximal muscles in comparison to
other MUNE methods. The use of DQEMG could be incorporated into larger studies to
help identify DPN patients in the early stages of neuromuscular degeneration allowing for
earlier, and perhaps more effective intervention.
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Chapter 4
4

Increased neuromuscular transmission instability and motor unit
remodeling with diabetic neuropathy as assessed using novel near
fibre motor unit potential parameters3

4.1

Introduction
Diabetic polyneuropathy (DPN) is a progressive neuropathic disorder

characterized by distal axonal loss1 and impaired regeneration2. Early signs and
symptoms may be predominantly sensory in nature3, however there is known
involvement of the motor system, including loss of motor axons or motor units4–7 which
has been associated with muscle weakness6. Electrophysiologically, the demyelinating
component of this neuropathy can be evaluated through nerve conduction studies (NCS),
however NCS provide limited information regarding axonal properties and no
information with regard to collateral reinnervation (axonal regeneration).
Standard concentric needle electromyography (NEMG) can provide more detailed
information regarding the denervation-reinnervation process underlying DPN8. This is
accomplished via the detection of spontaneous activity, polyphasic motor unit potentials
(MUPs), and also the quantification of MUP amplitude, duration, and number of turns, as
well as MU recruitment pattern8. Furthermore, the integrity of neuromuscular
transmission can be examined in greater detail through the assessment of the degree of
variability in the shape of consecutively detected MUPs9. Two key properties related to
MUP shape variability are termed jitter and jiggle9,10. Jitter refers to the variability of the
time intervals between pairs of individual muscle fibre potentials from a single MUP, and
jiggle refers to the variability in overall MUP shape from one MUP discharge to the next.
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Increases in both jitter and jiggle have been reported under conditions of neuromuscular
transmission disturbance and can reflect early axonal denervation5,11,12. Additionally,
increases in MUP instability (and thus jitter and jiggle) can be caused by variability in
muscle fibre action potential velocity, a finding present in various myopathies13–15.
Specific to DPN, a previous study using single fibre electromyography (SFEMG) found
increased jitter in the tibialis anterior (TA) of patients with DPN, however jiggle was not
reported5. Additionally, increased fibre density in patients with DPN compared to
controls was observed, which is indicative of reinnervation presumably to compensate for
prior denervation (motor unit remodeling)5. It is not known how jitter and jiggle may
relate to functional parameters such as strength or fatigue, however they may share a
negative association as the disturbances that lead to increased neuromuscular instability
may also be a factor related to a decrease in strength.
Novel parameters of near fiber (NF) MUPs have been developed. A NF MUP is
calculated by high-pass filtering a MUP template waveform, and therefore is primarily
comprised of contributions from fibers that are close to the needle detection surface16,17.
NF MUP parameters include: NF count (which, as described in Stashuk 199917, is a
measure of fiber density), NF jiggle (which can be used to assess the neuromuscular
transmission variability of the near fibers), NF dispersion (which measures the temporal
dispersion of the near fiber contributions) and maximum NF interval (which is the
maximum time interval between consecutive near fiber contributions to a NF MUP). NF
MUP parameters theoretically can provide similar types of information as traditional
MUP analysis (i.e. metrics of motor unit size (MUP amplitude, duration or area), fiber
contribution dispersion (MUP # of phases or turns), and neuromuscular transmission
instability (MUP jiggle)). However, because NF MUP parameters are dependent on the
configuration and activity of the subset of motor unit fibers that are close (within ~350
µm) to the needle detection surface17–20 they can potentially provide more robust and
detailed information concerning neuromuscular transmission variability and motor unit
remodeling in comparison to conventional MUP parameters. This is particularly relevant
when the MUPs and NF MUPs analyzed were extracted from a moderately complex
interference pattern using electromyographic (EMG) signal decomposition methods (see
Methods 4.2.3). At present, no study has reported these NF MUP parameter values for
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patients with neuropathy, although it is expected that the general characteristics
associated with neuropathic MUPs (increased size, complexity, and instability) will also
be evident in neuropathic NF MUPs.
All of the aforementioned MUP and NF MUP parameters are obtained using a
concentric needle-electrode and decomposition-based quantitative electromyography
(DQEMG) software16,17. DQEMG also provides data pertaining to motor unit firing rates
and firing rate variability, as well as relative motor unit size, via surface motor unit
potentials (SMUPs)7,21,22. In addition, if a maximal compound muscle action potential
(CMAP) waveform is appropriately recorded, DQEMG can be used to calculate a motor
unit number estimate (MUNE), which can provide further insight regarding the
denervation of a muscle7,21,22.
The present study was designed to assess the effects of DPN on standard MUP
and novel NF MUP parameters including NF jiggle, NF dispersion and maximum NF
interval, compared to age and sex-matched controls. We compared results from the novel
NF MUP parameters to standard MUP parameters including number of turns, area and
traditional jiggle. Additionally we related measures of neuromuscular transmission
variability and motor unit remodeling to dorsiflexion strength. Finally, we examined how
changes in individual motor unit size, due to the DPN-associated denervationreinnervation process, are related to NF MUP stability during sustained, low-level
isometric contractions in patients with DPN. We hypothesized the following: (i) DPN
patients would possess motor units with greater mean NF fiber count, NF jiggle, NF
dispersion, and maximal NF interval; (ii) NF fiber count, NF jiggle and NF dispersion
would be negatively related to dorsiflexion strength; and (iii) positive relationships would
exist between standard parameters of MUP size and NF fibre count, NF jiggle and NF
dispersion.
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4.2 Methods
4.2.1

Participants
Twelve patients (7 men, 5 women; ages 32-78 years) with DPN were recruited.

They met the criteria for diagnosis of type 2 (non-insulin dependent) diabetes mellitus
(DM) with clinical and electrophysiological characteristics of confirmed DPN23.
Additionally, patients received a thorough consultation and electrophysiological
examination by an experienced neurologist with specialized training in neuromuscular
disease to exclude other causes of nerve injury (i.e., other polyneuropathies, compressive
mononeuropathies or radiculopathies). Patients with any neurological, metabolic or
vascular diseases other than related to DM or DPN were excluded. Twelve healthy, age
and sex-matched controls (7 men, 5 women; ages 29-77 years) were recruited from the
community. Control participants were screened by physicians (neurologists) to ensure
they met inclusion criteria. The study was approved by the local university research
ethics board. Informed oral and written consent was obtained from all participants prior
to testing.
4.2.2

Tibialis Anterior DQEMG Data Acquisition
For the present investigation, the TA was selected due to its known involvement

in DPN6,7 and its high-degree of accessibility for needle EMG study. Participants were
seated in a custom isometric dynamometer designed to measure plantar and dorsiflexion
at the ankle joint24. In the dynamometer, the right ankle was positioned at 30° of plantar
flexion, with both knee and hip angles maintained at 90°. A C-shaped brace was secured
directly on the distal aspect of the right thigh to minimize movement at the hip joint
during contractions. Inelastic Velcro straps were placed over the dorsum of the foot to
secure the foot to the dynamometer25.
All testing was performed on the right (dominant) leg. Participants performed
three dorsiflexion maximal voluntary contractions (MVCs), with at least 3 min of rest
between attempts. Each MVC was held for approximately 3 seconds. Participants were
provided with real time visual feedback of their torque and verbally encouraged.
Voluntary activation during the 2nd and 3rd MVC attempts was assessed using the

68

interpolated twitch technique (ITT)26. This technique involves supramaximal
percutaneous electrical stimulation of the fibular nerve just distal to the fibular head. The
amplitude of the interpolated torque electrically evoked from a single 100 µs stimulus
during the plateau of the MVC was compared with a single (100μs) resting twitch evoked
~1s following the MVC. Voluntary activation was calculated as a percent using the
following equation: [1- (interpolated twitch /resting twitch)] x 100. The ITT allows the
operator to ensure the participant is providing a maximal voluntary effort during their
MVC. The peak torque of the three MVC attempts was taken as the maximal torque for
the participant. All torque signals were collected and sampled online at 500 Hz using
Spike2 software (Version 7.11; Cambridge Electronic Design Ltd., Cambridge, United
Kingdom) and analyzed off-line to determine voluntary isometric torques (strength).
Surface EMG signals were recorded from the TA using self-adhering Ag-AgCl
electrodes (1 cm x 3 cm). The active electrode was placed over the TA motor point,
approximately 7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior border of
the tibia. This placement was adjusted as needed to maximize the TA CMAP
amplitude. The reference electrode was placed over the distal tendon of the TA. A ground
electrode was placed over the patella.
DQEMG EMG data were acquired using the protocol described in detail
elsewhere16,27. Intramuscular EMG signals were recorded via a disposable concentric
needle electrode (Model N53153; Teca Corp., Hawthorne, NY) inserted into the TA, 5-10
mm distal to the active surface electrode. The surface and intramuscular EMG signals
were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz, respectively. Surface EMG
signals were sampled at 3 kHz; intramuscular EMG signals were sampled at 30 kHz. To
evoke the maximum CMAP a bar electrode held distal to the fibular head delivered
supramaximal electrical stimuli to the common fibular nerve. Subsequently, participants
matched a target line of 25% MVC, visible on a computer monitor, for all isometric
dorsiflexion contractions. Prior to engaging in these contractions, the intramuscular
needle electrode was inserted and manipulated in the muscle. This contraction intensity
has been shown to be the most effective intensity for obtaining a representative MUNE in
the tibialis anterior (TA)25. Surface and intramuscular EMG signals were recorded during
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a sustained 25% MVC contraction, which was held for ~30 seconds. Between
contractions, the concentric needle electrode was repositioned in order to sample different
motor units. These procedures were repeated until at least 20 suitable MUP trains and
their respective surface-motor unit potentials (S-MUPs) were acquired.
4.2.3

Tibialis Anterior Decomposition-based Quantitative Electromyography
Analysis
Decomposed intramuscular EMG signals were reviewed off-line to determine the

acceptability of the extracted MUP trains and their corresponding S-MUPs. MUP trains
were inspected visually to ensure that their MUP occurrence patterns were consistent
with the expected activity of a single motor unit (consistent firing pattern and
interdischarge coefficient of variation of < 0.3). Invalid MUP trains and their associated
S-MUPs were excluded from further analyses. The DQEMG algorithms estimate a MUP
and S-MUP template waveform. For these waveforms DQEMG automatically places
markers related to onset, end, negative peak and positive peak positions. All MUP and SMUP markers were subsequently reviewed visually by the operator. A MUNE was
derived by dividing the negative-peak amplitude of the maximal CMAP by the negative
peak amplitude of the mean S-MUP21,22. These MUNE results have been previously
reported7.
The DQEMG algorithms also provide measures of the overall needle EMG signal
intensity (measured in pulses per second), mean firing rates (Hz) of individual motor
units based on their extracted MUP trains, and an overall mean firing rate per participant
at a relative target level of contraction (25% of MVC). Additionally, the DQEMG system
automatically calculates standard parameters of the MUP template, including peak-topeak amplitude, area, duration and traditional jiggle. For the assessment of MUP stability,
used to reflect neuromuscular transmission variability, MUPs that represent the isolated
activity of a single motor unit are automatically selected by the DQEMG algorithms. The
sets of automatically selected isolated MUPs were manually inspected and any MUPs
found to be significantly contaminated by the activity of other motor units were removed
and replaced. The DQEMG technique described has been shown to possess similar testretest values within individuals28, and high degrees of intra- and inter-rater reliability in
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control and clinical populations29,30. The investigator was blinded to the status of the
participant (DPN patient vs control) during off-line analysis.
4.2.4

Novel Near Fibre Motor Unit Potential Parameters

4.2.4.1 Near Fibre MUP Template
The MUP template provided by the DQEMG algorithms is high-pass filtered
using a second ordered low-pass differentiator17,31. The second order filter equation is:
xt = yt+2 – yt+1 – yt + yt-1
Where yt is the sampled raw signal and xt is the sampled filtered signal31. Due to
the spatial low-pass filtering properties of volume conduction, the resulting near fibre
MUP template waveform, or NF MUP, is primarily comprised of contributions from
fibres that are ‘near’ (within ~350 µm) to the detection surface of the needle electrode.
The NF MUP can be used to focus on characteristics of the near fibres and is
defined as a MUP contributed to by the fibers that are close to the detection surface of the
needle electrode. In contrast, a NF contribution is the specific contribution of an
individual NF (an individual muscle fibre) to a NF MUP. The temporal relationships of
the near fibre contributions may be more easily determined than relationships among all
contributing fibres as would be the case when analyzing MUPs collected using only
traditional Butterworth filtering. This is due to the spatial filtering used to create NF
MUPs, which filters out more distant volume conducted MU activity that could
potentially reduce the ability to detect individual muscle fibre. As such, by focusing on
the near fibre contributions measures of the temporal dispersion of these near fibre
contributions can be obtained. These measures in turn can be used to reflect the relative
conduction times of the muscle fibre action potentials to the detection surface of the
electrode. Assuming similar conduction velocities across the fibres of a motor unit which
may not be true in disease, the temporal dispersion of NF contributions can therefore
reflect the relative conduction distances of the axonal and muscle fibre action potentials.
With presumed similar conduction distances along the muscle fibres, temporal dispersion
can reflect the degree of axonal sprouting in the motor unit and provide evidence of
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reinnervation. Figure 4.1 displays a MUP and its associated NF MUP as well as
important aspects of the NF MUP parameters described below.
4.2.4.2 Near Fibre Parameters
Near fibre duration (NF Dur) is the time between the onset and end positions of
the near fibre MUP. The NF MUP onset and end positions are calculated by applying the
same criteria used to calculate the MUP onset and end positions. Near fibre area (NF
Area) is the sum of the absolute area under the curve of the NF MUP between the onset
and end positions multiplied by the sampling interval (i.e. 1/ (sampling rate)).
Near fibre count (NF fiber count) is the number of detected near fiber
contributions to the NF MUP. A positive turn detected in the NF MUP with sufficient
symmetry and amplitude is considered a distinct near fiber contribution. The NF fiber
count reflects the density of fibers in the motor unit.
Near fibre dispersion (NF dispersion) can be used to assess reinnervation, and is
the time interval between the first and last detected fiber contribution to the NF MUP.
The maximum near fibre interval (max NF Interval) is the maximum time
between consecutive detected near fiber contributions. Large max NF interval values may
indicate long reinnervating axonal sprouts. Large max NF intervals values may relate to
traditionally identified satellite potentials.
Near fibre jiggle (NF jiggle) is a statistic that measures the variability of
consecutive isolated NF MUPs of a MUP train. The statistic is the same as introduced by
Stalberg applied to the MUPs of a MUP train10. The NF MUPs of a MUP train are
created by high-pass filtering each MUP using the same second ordered low-pass
differentiator used to create the NF MUP template. Isolated NF MUPs are selected as
described previously17.
Near fibre jitter refers to the mean consecutive difference value measured for a
pair of detected distinct fiber contributions within a NF MUP across the NF MUP
train10,17. Suitable muscle fibre pair tracking was confirmed by visual inspection. In
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addition, % blocking was assessed for all pairs of detected fiber contributions across the
sets of isolated NF MUPs. % blocking is indicative of the rate at which an individual
muscle fibre fails to propagate an action potential following the activation of its motor
neuron. This is measured by counting the number of intermittent absences of an
individual NF contribution to the NF MUPs of the set of isolated NF MUPs analyzed10.
4.2.5

Inter-Rater Reliability of DQEMG NF Jiggle Analysis
To provide an assessment of the inherent variability of DQEMG-derived NF

jiggle, a second examiner performed the DQEMG NF MUP analysis described above on
a pseudo-random subset of the collected data (6 controls, 6 DPN patients). A reliability
assessment of NF jiggle was appropriate as there is some subjective decision-making
regarding the inclusion and exclusion of NF MUPs for stability analysis due to signal
contamination from adjacent motor units. Data analysis by each examiner was performed
independently, and examiners were blinded to participant status during analysis. Each
rater remained blind to the results of the other examiner until data collection and
respective analyses were complete for all participants.
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Figure 4.1 Electromyographic tracings of motor unit potential and near fibre motor unit
potential
Electromyographic tracings from decomposition based quantitative electromyography
(DQEMG) of a sample (A) motor unit potential (MUP), and (B) the corresponding near
fibre (NF) MUP. On the NF MUP tracing (B), numbers 1, 2, 3 and 4 represent NF
contributions, providing the NF fibre count. NF dispersion is calculated as the duration
between 1 and 4. Maximal NF interval is calculated as the duration between 2 and 3.
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4.2.6

Statistics
Mean values ± standard deviations are presented in the text. Normally distributed

data were analyzed using a one-way ANOVA; the level of significance was set at P ≤
0.05. Normality was assessed using a Shapiro-Wilk test. Non-normally distributed data
were analyzed using a Kruskal-Wallis one-way ANOVA on ranks. Relationships among
variables were tested using Pearson’s Product Moment Correlation. To represent the
degree of differences between groups, effect sizes between group MUP and NF MUP
parameter values were calculated using Cohen’s D. Relative inter-rater reliability was
tested using a Model 2 (two-way random, absolute agreement) single measure intra-class
correlation coefficient (ICC). ICC point estimates were considered ‘poor’ (<0.50),
‘moderate’ (0.50 – 0.75) or ‘good’ (>0.75)32. Data analyses were performed using
SigmaPlot software (Version 12.2; Systat Software, Chicago, Illinois, US) excluding the
ICC calculation which was performed using SPSS (Version 20.0; SPSS, Chicago,
Illinois, US).

4.3 Results
Participant characteristics are presented in Table 4.1. No significant differences
were detected for age (p>0.05) or height (p>0.05) between groups. DPN patients had
significantly greater body mass (p<0.05) and BMI (p<0.05) than controls. Data
characterizing the clinical history and status of the DPN patient group are also presented
in Table 4.1.
Dorsiflexion strength and standard MUP parameters and MUNE values7 are
presented in Table 4.2. The DPN patients had smaller CMAPs compared to controls (6.8
vs 5.0 mV; p<0.05), however the mean CMAP value for the patient group was not below
our clinical laboratory’s lower limit of normal (4.0 mV). DPN patients had fewer motor
units (-45%) and were weaker (-35%) than controls (p<0.05), but no group differences
were detected with respect to traditional jiggle (p>0.05). Both DPN patients and controls
were able to achieve near-maximal (>95%) voluntary activation during MVCs as
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assessed using the ITT. Finally, the DPN group had larger (+47% MUP area) MUPs with
significantly more turns (+21%) compared to controls (p<0.05).
NF MUP parameter values are presented in Table 4.3. DPN patients had greater:
NF area (+40%), NF duration (+24%), NF dispersion (+38%) and maximal NF interval
(+22%) compared to controls (p<0.05). Additionally, NF jiggle was found to be greater
in DPN patients versus controls (+21%; p<0.05), and NF jiggle was found to have a
‘good’ level of inter-rater reliability (ICC = 0.81). In comparison with controls, DPN
patients had increased NF fibre counts (+31%) and greater NF jitter values (+34%;
p<0.05). In comparing how DPN patients differed from controls in standard MUP
parameters and NF MUP parameters, differences in NF MUP parameters tended to have
greater effect sizes (Tables 4.2 and 4.3). The largest magnitude of effects were found for
NF fibre count and max NF interval (d = 1.76 and 1.51, respectively; Table 4.3). In
comparison, most standard MUP parameters had effect sizes less than 1.0 (Table 4.2).
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Anthropometric Parameters
Male/Female
Age (years)
Height (m)
Weight (kg)
BMI (kg/m2)

Control (n = 12)
7/5
63.8 ± 15.5
1.8 ± 0.1
73.8 ± 6.1
24.4 ± 3.1

DPN Patient (n = 12)
7/5
65.8 ± 15.4
1.7 ± 0.1
83.1 ± 7.4*
28.9 ± 3.7*

Diabetic Characteristics
Duration of Diabetes (years)
Duration of DPN (years)
HbA1c (%)

Range or Limit of Normal
<6.0

14.1 ± 11.2
9.2 ± 8.1
7.4 ± 1.4

Nerve Conduction Studies
Sural Nerve SNAP Amplitude
(µV)
TA CMAP amplitude (mV)
Fibular nerve CV (m/s)

Range or Limit of Normal
>5

1.3 ± 2.3#

>4.0
>40.0

5.0 ± 1.7
41.4 ± 10.4

Table 4.1 Participant Characteristics
* Denotes significant difference between groups (p<0.05).
SNAP – sensory nerve action potential; TA – tibialis anterior; CMAP – compound
muscle action potential; CV – conduction velocity; DPN – diabetic polyneuropathy. #
SNAP responses were absent in 10 out of 12 patients.
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Parameter
Dorsiflexion MVC Strength (Nm)

Controls (n=12)
34.1 ± 9.5

DPN Patients (n=12)
22.3 ± 7.2*

% Difference
-35%

Effect Size
1.39

%MVC RMS EMG

23.2 ± 4.2

25.2 ± 3.8

EMG Intensity (pps)

74.3 ± 20.2

55.6 ± 19.2*

-25%

0.94

Mean MU FR (Hz) at 25% MVC

12.10 ± 1.80

10.2 ± 1.2*

-15%

1.24

MUP Vpp (µV)

810.4 ± 217.0

1164.3 ± 493.0*

+43%

0.92

MUP Duration (ms)

12.3 ± 2.1

14.4 ± 2.2*

+17%

0.97

MUP Area (µVms)

1436.5 ± 503.6

2117.5 ± 991.1*

+47%

0.86

1.77 ± 0.22

1.8 ± 0.3

Shape Width (ms)

0.7 ± 0.1

0.7 ± 0.1

Turns (#)

4.2 ± 0.7

5.1 ± 0.9*

+21%

1.11

36.4 ± 21.0

25.4 ± 20.7

CMAP (mV)

6.8 ± 0.9

5.0 ± 1.7*

-26%

1.32

mSMUP (µV)

77.0 ± 20.0

116.0 ± 61.0*

+51%

0.85

99 ± 19

54 ± 25*

-45%

2.02

AAR (ms)

Traditional Jiggle (%)

MUNE (#)

Table 4.2 Tibialis Anterior Strength, MUP and MUNE Parameters
* Denotes significant difference between groups (p<0.05). Effect size calculated as Cohen’s D. MVC – maximal voluntary
contraction; RMS – root mean squared; EMG – electromyography; pps – pulses per second; MU – motor unit; MUP – motor unit
potential; Vpp – peak to peak voltage; AAR – area to amplitude ratio; CMAP – compound muscle action potential; mSMUP – mean
surface motor unit potential; MUNE – motor unit number estimate; DPN – diabetic polyneuropathy
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Parameter

Controls (n=12)

# of MUPTs

23.4 ± 1.6

DPN Patients
(n=12)
26.4 ± 3.4

% Difference
+13%

Effect
Size
1.13

Contractions (#)

4.4 ± 0.5

6.2 ± 2.5

+42%

0.99

NF Area (kV/s2ms)

6.9 ± 1.8

9.7 ± 3.0*

+40%

1.13

NF Duration (ms)

3.8 ± 0.7

4.7 ± 0.9*

+24%

1.12

NF Dispersion (ms)

1.7 ± 0.4

2.4 ± 0.9*

+38%

1.01

Max NF Interval (ms)

1.0 ± 0.2

1.3 ± 0.2*

+22%

1.51

NF Fibre Count (#)

2.5 ± 0.4

3.3 ± 0.5*

+31%

1.76

NF Jiggle (%)

33.8 ± 3.7

40.9 ± 6.3*

+21%

1.18

NF Jitter (µs)

37.6 ± 9.0

50.6 ± 14.2*

+34%

1.09

% of MUPTs w/

0.0 ± 0.0

17.1 ± 7.9*

+17%

3.06

0.0 ± 0.0

3.7 ± 1.3*

+4%

4.02

blocking
% Blocking

Table 4.3 Neuromuscular Transmission Stability and Near Fibre Parameters
* Denotes significant difference between groups (p<0.05). Effect size calculated as
Cohen’s D.
MUPT – motor unit potential train; NF – near fibre; DPN – diabetic polyneuropathy
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NF MUP size parameters were positively related to MUP area, the conceptually
analogous standard MUP size parameter. NF area was positively related to MUP area in
both controls (r = 0.67; p<0.05) and DPN patients (r = 0.55; p<0.05). NF duration was
positively related to MUP area in controls (r = 0.45; p<0.05) and DPN patients (r = 0.35;
p<0.05). Also, in both controls (r = 0.64; p<0.05) and DPN patients (r = 0.81; p<0.05),
NF dispersion (a measure of fiber contribution dispersion) was positively associated with
MUP area.
NF MUPs with greater numbers of fibre contributions tended to be larger in size.
This is supported by the result that NF area was positively related (controls, r = 0.60;
DPN patients, r = 0.51; p<0.05) with the number of distinct muscle fibres detected within
that NF MUP (NF count) (Figure 4.2). Furthermore, NF jiggle was not related to MUP
area (p>0.05), indicating acute neuromuscular instability was not associated with a
traditional metric of motor unit size. However, NF jiggle was positively associated with
NF fibre count (Figure 4.3; r = 0.46; p<0.05).
NF dispersion, but not stability, was associated with whole muscle denervation.
Specifically, NF jiggle values were not significantly related to dorsiflexion strength or
TA MUNE values (p>0.05) (Figure 4.4A and 4C; p>0.05); whereas, in DPN patients, NF
dispersion was negatively related to MUNE (Figure 4.4D; r = -0.63; p<0.05) but not
strength (Figure 4.4B; p>0.05). Finally, no significant relationships were found between
NF MUP parameters and duration of DM (p>0.05), duration of DPN (p>0.05) or
glycemic control values (HbA1c levels) (p>0.05).
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Figure 4.2 Relationship between near fibre (NF) fibre count and NF motor unit potential
area
Relationship between near fibre (NF) fibre count and NF Area in the tibialis anterior of
controls (grey circles; r = 0.60 [grey line]) and diabetic polyneuropathy (DPN) patients
(black circles; r = 0.51 [black line]). In both groups, NF motor unit potentials (MUPs)
with greater NF fibre counts had larger NF MUP areas.
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Figure 4.3 Relationship between near fibre (NF) fibre count and NF jiggle
Relationship between near fibre (NF) fibre count and NF Jiggle in the tibialis anterior of
controls (grey circles) and diabetic polyneuropathy (DPN) patients (black circles; r =
0.46). In DPN patients, increased fibre counts were associated with increased NF
instability (black line). No relationship was detected between these variables in controls
(grey line).
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Figure 4.4 Relationships between tibialis anterior health, strength and neuromuscular transmission stability
Relationships between (A) dorsiflexion maximal voluntary contraction (MVC) strength and NF Jiggle; (B) dorsiflexion MVC strength
and NF dispersion; (C) motor unit number estimates and near fibre (NF) Jiggle; and (D) motor unit number estimates and NF
dispersion (DPN r = -0.63) in controls (grey circles) and diabetic polyneuropathy (DPN) patients (black circles). Relationships for
control participants are denoted by grey lines; relationships for DPN patients are denoted by black lines.
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4.4 Discussion
The main findings of this study were: (1) patients with DPN had larger (NF area,
NF duration), more complex (NF dispersion, NF fibre count) and less stable NF MUPs
(NF jiggle, NF jitter), compared to controls; (2) NF dispersion was positively related to
whole muscle denervation (MUNE) but not strength, whereas NF MUP stability (NF
jiggle) was not related to either strength or whole muscle denervation; (3) NF MUPs with
a greater number of distinguishable near fibre contributions tended to be less stable,
although no relationship was found between NF jiggle and NF area; (4) NF parameters
were not significantly related to metrics of disease duration or glycemic control.
4.4.1

Near Fibre versus Traditional MUP Parameters in Diabetic Polyneuropathy
In the present study, patients with DPN had clear evidence of DM and DPN

through their clinical assessment, elevated glycosylated hemoglobin (HbA1c) levels and
reduced or absent sural sensory nerve action potential amplitudes (SNAPs) (Table 4.1).
Our traditional MUP (Table 4.2) and NF MUP (Table 4.3) results show increased
neuromuscular transmission instability and fibre density in patients with DPN. Although
this finding is consistent with a prior report that used traditional single-fibre EMG5, the
present study extends these observations by using novel quantitative concentric needlederived EMG measures (NF MUP parameters).
In the present study, traditional jiggle was not different between groups (p>0.05)
whereas NF jiggle was significantly greater in patients with DPN compared to controls
(Table 4.3; p<0.05). These divergent findings in two metrics purported to assess the same
variable (i.e. neuromuscular transmission instability) support the idea that when
analyzing intramuscular EMG signals detected using concentric needle electrodes during
moderate level (25% MVC) contractions, NF MUP parameters may be more robust than
standard MUP parameters17. Traditional jitter measured using concentric needle detected
MUPs have been reported before in other neuropathic conditions33,34, and its advantages
over SFEMG have been outlined34. However, our study appears to be the first to perform
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this technique with DQEMG software, to present concentric needle acquired jiggle data,
and to report NF MUP parameters in a chronic neuropathic condition.
The lack of any significant differences in traditional jiggle values between groups
in this study is surprising given our other results showing increased NF MUP instability
(NF jiggle) in DPN patients (Table 4.3), and the conclusions of previous investigations5.
However, one possible contributing factor to explain our finding may be the different
degrees of intensity of MUPs detected during the sustained voluntary contractions in
controls compared to patients with DPN (75 vs 55 pps respectively; Table 4.2). As a
consequence of their neuropathy, individuals in the DPN group have significantly
enlarged and fewer MUs compared to controls (Table 4.2)7. Thus, during a sustained
dorsiflexion contraction at 25% MVC, DPN patients are activating fewer MUs, and those
activated are discharging at lower firing rates (Table 4.2) leading to less intense
electromyographic interference pattern activity (-25% less pps; Table 4.2). The reduced
firing rates in DPN patients may reflect the slowing of muscle contractile properties35 or
preferential loss of fast motor units35. These group differences in recruitment patterns are
influential when examining MUP raster plots for stability analysis, as higher amounts of
electrophysiological ‘contamination’ from nearby MUs is apparent in the control data
versus that of the DPN patient group. This drives the traditional jiggle values artificially
higher in controls such that they may not reflect the true amount of neuromuscular
transmission instability. Compared to traditional jiggle, NF jiggle may be less affected by
this contamination as the focus is placed on MUs with fibers near (within ~350 µm) the
electrode detection surface, with minimal contributions from more distal fibres. This
technical limitation could be reduced by using lower voluntary contractile intensities5,10
or low-frequency, evoked contractions33. However performing contractions at 25% of
MVC provides two important advantages. Firstly, this contractile intensity includes a
greater, more representative sample of MUs from the muscle being examined, thus
allowing for a more comprehensive assessment of the muscle’s entire motor unit pool. In
contrast, other methods of measuring neuromuscular transmission instability have been
limited to low threshold motor units, at relatively low firing rates5,9. Secondly,
performing the protocol at 25% of MVC when using DQEMG allows for the
simultaneous calculation of a valid MUNE25, which is another important and useful
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measure related to neuromuscular health36,6,7. Indeed, reduced MUNEs in the DPN group
had one of the largest effect sizes across all parameters (Table 4.2), supporting the
inclusion of MUNEs as a useful clinical indicator. The specific MUNE results presented
in this study have been reported and discussed previously7.
In comparing NF MUP parameters, other than NF jiggle, with their respective
analogous traditional MUP parameters there is a stronger degree of correlation. NF area
and NF duration were significantly positively related to MUP area and MUP duration,
respectively. This indicates these NF MUP parameters are positively associated with
traditional metrics representing MU size. Additionally, NF area was positively related to
NF fibre count which indicates the NF MUP size is partially determined by the number of
near muscle fibres innervated by that particular motor unit (Figure 4.2). Similar to a
previous report in DPN examining traditional jitter, we found increased NF jitter in DPN
patients compared to controls (Table 4.3)5. It is important to note when comparing the
traditional MUP and NF MUP parameter results for the present study that the apparent
ability to discriminate between controls and DPN patients is greater using the NF MUP
parameters. Specifically, the majority of the NF MUP parameters had greater effects sizes
than standard MUP parameters (Tables 4.2 and 4.3). Indeed, the two parameters with the
largest effect sizes were NF fibre count (d = 1.76) and max NF interval (d = 1.51). Thus,
NF MUP parameters may prove more useful than standard MUP parameters in
distinguishing neuropathic from non-neuropathic MUs, however further study is required.
4.4.2

Physiological Interpretation and Clinical Relevance of Near Fibre MUP
Parameters
Our data showing increased NF jiggle and NF jitter in DPN patients relative to

controls may be reflective of pathological alterations in neuromuscular action potential
propagation, or neuromuscular transmission instability, due to DPN (Table 4.3).
Increased NF jiggle and NF jitter values primarily reflect the denervation-reinnervation
process acutely10. Specifically, increased neuromuscular transmission instability is
thought to occur in association with partial loss of innervation by a damaged motor axon,
or incomplete reinnervation occurring between orphaned muscle fibres and their adopted
axonal sprout during the process of collateral reinnervation10. In this instance, the concept
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of acute reinnervation is contrasted by chronic reinnervation in which mature
neuromuscular junctions have formed, and neuromuscular transmission variability has
recovered. Additionally, our data show an increased amount of neuromuscular
transmission failure (i.e. % blocking) in DPN patients compared to controls (Table 4.3).
A previous study in DPN using SFEMG did not include blocking as a measured
parameter5. Indeed, a greater contraction intensity would be more likely to challenge the
neuromuscular system and induce neuromuscular transmission failure37. This intermittent
transmission failure reflects the underlying dysfunction in processes related to
neuromuscular transmission, and would also directly lead to increases in NF jiggle and
NF jitter. However, it is unclear how potential dysfunction occurring at the site of distal
axonal branches; the neuromuscular junction; muscle fibre action potential propagation;
or some combination thereof, contribute to increased instability. Previous studies, mainly
relying upon animal models, provide evidence that DPN-related neuromuscular
instability could be due to a range of factors including: nerve demyelination and reduced
axonal calibre38; axon terminal dysfunction39; ion channel alterations39–41; or structural
changes at the muscle fibre39,42, among other possible mechanisms. Any of these putative
changes within the neuromuscular system could differentially affect muscle fibre action
potential conduction velocity43, consequently affecting MUP shape stability. Assuming
these diabetes-related neuromuscular changes would not occur uniformly, nor have a
consistent effect on action potential propagation across terminal axon branches or muscle
fibres within a single motor unit, they could result in increased NF jiggle and NF jitter. In
comparison, our results showing increased NF dispersion, max NF interval and NF fibre
count in DPN are most likely representative of prior compensatory reinnervation that has
occurred following muscle fibre denervation4,7.
We did not find any relationships between neuromuscular transmission instability
(NF jiggle) and whole muscle denervation (MUNE) or muscle strength (Figures 4.4C and
4.4A; p>0.05). NF jiggle and MUNE may not have been related to one another as they
reflect different aspects of the denervation-reinnervation process. Whereas increased NF
jiggle may indicate acute, or on-going, denervation or reinnervation, a decreased MUNE
represents denervation that is complete. Therefore it may be possible that individuals who
have lost many motor units may possess fewer, enlarged, but relatively stable motor
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units. Indeed, no significant relationship was found between NF jiggle and MUP area
(p>0.05). Notwithstanding, there was a tendency for MUPs with greater numbers of
distinguishable near fibre contributions to be less stable than their counterparts with
fewer distinguishable near fibre contributions (Figure 4.3). This occurs perhaps because a
motor unit that is sprouting axons to reinnervate denervated fibres will have a greater
chance of having immature or nascent neuromuscular junctions which in turn will be
unstable and lead to higher jitter and therefore contribute to higher jiggle. NF jiggle and
strength did not correlate as increased neuromuscular transmission instability does not
necessitate concurrent muscle atrophy or functional decrement. In contrast, in the DPN
patients, NF dispersion was negatively related to MUNE (Figure 4.4D). This is likely due
to increased NF dispersion representing prior motor unit remodeling that occurs
following denervation (or a decrease in MUNE). Given these relationships, our results
indicate the assessment of NF jiggle may be most useful in identifying patients in the
early stages of neuromuscular pathology, prior to the development of detectable motor
unit loss or decreases in strength.
Our NF MUP stability parameters were not significantly related to the duration of
DM or DPN, or glycemic control as expressed by HbA1c values. This is in contrast to
one previous finding in which traditional jitter, derived from SFEMG, correlated
positively with HbA1c5. The difference in findings may be attributed partially to the
complex, multi-factorial nature of DPN. Some factors that may interact and effect
neuromuscular transmission instability include: disease duration, disease severity,
glycemic control5, adult aging, physical activity history, and natural biological variability.
The effects and importance of these, and other factors, likely will require studies with
greater numbers of participants.
4.4.3

Conclusions
We have demonstrated concentric needle-derived DQEMG can be used to detect

increased neuromuscular transmission instability and motor unit remodeling in patients
with DPN. Additionally, in a chronic neuropathic condition, we present NF MUP
parameters and support their inclusion as potentially useful metrics concerning
neuromuscular stability and motor unit remodeling relative to controls. Indeed, NF MUP
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parameters may have enhanced clinical utility in detecting neuropathic abnormalities
compared to standard MUP parameters. Our results show NF MUPs with greater
numbers of distinct near fibre contributions are less stable. Changes in neuromuscular
transmission instability do not appear to closely associate with whole muscle
denervation; perhaps as a result of the development of stable motor axon-muscle fibre
synapses as the collateral reinnervation process progresses. The presence of
neuromuscular transmission blocking in DPN patients may have consequences
concerning neuromuscular function under conditions that stress the capacity of the
system, such as fatiguing contractions. Finally, NF jiggle may be useful in identifying
patients in the early stages of neuromuscular disease, prior to the loss of motor units or
onset of muscle weakness.
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Chapter 5
5

Skeletal muscle morphology and contractile function in relation to
muscle denervation in diabetic neuropathy4

5.1

Introduction
Diabetes mellitus (DM) and its common complication, diabetic polyneuropathy

(DPN) are associated with changes in the neuromuscular system and motor dysfunction1.
Motor dysfunction as a result of DPN can manifest broadly as muscle atrophy, weakness,
and increased susceptibility to fatigue2–6. These changes may be due to a combination of
DM-induced alterations to the α-motor neuron, neuromuscular junction, and skeletal
muscle fibres7,8. Despite many studies conducted using diabetic animal models, relatively
few have attempted to directly quantify neuromuscular and motor unit properties in
humans with DPN. Thus the current study was aimed at investigating alterations in
contractile properties and morphology of skeletal muscle in patients with DPN in
association with changes in motor unit properties and denervation.
In rodent models of DM, weakness, as measured through induced tetanic
stimulation, has been attributed partially to muscle atrophy, particularly in fast-twitch
fibres9. However, reduction in strength persists when muscle is compared relative to
weight9 or cross-sectional area10. Studies investigating DPN in humans have reported
length-dependent atrophy of skeletal muscle using magnetic resonance imaging (MRI)
and dual energy x-ray absorptiometry (DXA) imaging techniques, in association with
weakness3,4,11. Strength loss in DPN has also been linked to excess fat infiltration of
skeletal muscle12 and preferential loss of type II muscle fibres related perhaps to their
selective denervation13. Other studies using experimental rodent models of DPN report

4

A version of this chapter has been published. Used with permission from the American
Physiological Society.
Allen, M.D., Major, B., Kimpinski, K., Doherty, T.J., Rice, C.L. Skeletal muscle
morphology and contractile function in relation to muscle denervation in diabetic
neuropathy. J Appl Physiol 116:545-552, 2014.
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distal motor axon or neuromuscular junction deficits, as well as excitation-contraction
uncoupling and disruption of Ca2+ handling as contributing factors to strength loss7,14,15.
Thus, there is no consensus on which factors, or combination of key factors explains DM
or DPN-associated weakness in humans or rodents. In humans with DPN, a potential
unexplored source and complication of muscle weakness may be due to increased
antagonist coactivation. In other neurological disorders (i.e. stroke, muscular dystrophy,
Parkinson’s disease), increased levels of coactivation have been reported to contribute to
muscle weakness16,17 which may occur as a compensatory strategy to maintain joint
stability. In addition to weakness, reductions in ankle plantar and dorsiflexion isokinetic
muscle power12 and rate of torque development13 have been reported in DPN patients12,13.
These changes have been associated with decrements to balance and physical function.
To date, the relationships between muscle morphological changes and reduction in rate of
torque development with a quantification of denervation, or motor unit loss, have not
been explored in DPN patients.
Whereas a loss of power production in DPN patients may be accounted for partly
by a loss in strength, a reduction in contractile velocity could also play an important role.
Studies investigating neuromuscular function in healthy adult aging have explored this
link18. In diabetic rodent skeletal muscle, reduced contractile speed of muscle fibres has
been shown9,10,15,19, however these studies have utilized rodent models of diabetes, and
mechanically skinned single-muscle fibre preparations, and thus the translation of these
results to humans is unclear. A study in the tibialis anterior (TA) of humans reported no
differences in evoked contractile properties between patients with DM and controls20, but
it is important to note the patient group studied featured DM, and not DPN. The presence
of DPN could reflect a longer duration or more severe history of DM, and indeed DPN
can result directly in greater muscle atrophy, weakness and neuromuscular remodeling
than DM alone21,22. Indeed, DPN has been associated with reduced motor unit number
estimates (MUNEs)23,24, although how this chronic process of muscular denervation may
affect muscle morphology has not been comprehensively explored.
Additionally, the potential slowing of muscle contractile properties has been
purported to be associated with reduced motor unit (MU) firing rates25. Previous
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investigations in rodent and human muscle have found muscle fibre contractile velocities
match the firing rate properties of the motor neurons supplying their innervation26,27. This
has been reported for some muscles in humans in relation to adult aging, including the
TA28. It is conceivable that the lower maximal motor unit firing rates reported in DPN
patients may be linked with slowed contractile properties relative to controls. However,
although contractile slowing has been reported numerous times in rodent models of DM
and DPN, this slowing has not been shown in humans with DPN.
The purpose of this study was to assess the neuromuscular contractile properties of the
TA in patients with DPN in comparison to age and sex-matched controls. The TA was
selected because it is generally observed to be affected by DPN earlier and to a greater
extent than more proximal muscles29, and it has a more important functional role in
everyday tasks compared to more distal muscles (i.e. intrinsic muscles of the feet). Our
specific objectives were three fold: (1) to investigate evoked twitch and voluntary
contractile properties of dorsiflexors, including antagonist (plantar flexor) co-activation;
(2) to determine peak TA muscle cross-sectional area (CSA), normalized strength
(strength per unit of muscle tissue) and relative contractile and non-contractile tissue; (3)
and to determine the relationship of the morphological measures stated above as they
relate to TA denervation. We hypothesized patients with DPN would have slowed
contractile properties compared to controls. Conjunctly, we hypothesized slowed
contractile properties in DPN patients would be positively associated with lower mean
firing rates (relative to controls) in TA motor units during a sustained, low intensity
dorsiflexion contraction. We hypothesized patients with DPN would be weaker and
demonstrate lower maximal rates of torque development during maximal isometric
voluntary contractions (MVCs), and that these decrements would be positively related to
increased antagonist co-activation. Additionally, we hypothesized DPN patients would
possess smaller TA CSAs with greater relative amounts of non-contractile tissue which
would be negatively related to the number of functioning motor units estimated in the
TA.
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5.2 Methods
5.2.1

Participants
With ethical approval from the local university’s Research Ethics Board,

informed oral and written consent was obtained from twelve patients (7 men, 5 women;
ages 32-78 years) with DPN. These patients met the criteria for diagnosis of type 2 noninsulin dependent DM with clinical and electrophysiological features of confirmed
DPN30. The majority of DPN patients were being treated with medications pertaining to
glycemic control (i.e. metformin and/or insulin) and antihypertensives. Additionally, they
had a thorough history, and clinical and electrophysiological examination by an
experienced neurologist with specialized training in neuromuscular disease to exclude
other causes of nerve injury and or neuropathy (i.e., compressive mononeuropathies or
radiculopathies), and other neurological, metabolic or vascular conditions unrelated to
DM or DPN. To provide electrophysiological evidence of neuropathy all DPN patients
underwent motor nerve conduction studies of the fibular nerve while recording from the
TA, as well as sensory nerve conduction studies of the sural nerve while recording from
the ankle. Data regarding blood lipid profiles and glycemic control were obtained through
chart review. The DPN patient group was compared with twelve healthy, age and sexmatched controls (7 men, 5 women; ages 29-77 years) who were recruited from the
community. Control participants were recreationally active, living independently in the
community, free from medications and were screened by physicians (neurologists) to
ensure they met inclusion criteria.
5.2.2

Evoked Contractile Properties and Strength of Tibialis Anterior
To assess voluntary and electrically stimulated properties of the TA, participants

were seated in a custom isometric dorsiflexion dynamometer31. The right ankle was
positioned at 30° of plantar flexion, while both knee and hip angles were maintained at
90°. Movement at the hip was minimized by securing a padded, C-shaped brace to the
distal aspect of the right thigh. Inelastic straps were wrapped over the dorsum of the foot
to secure the foot to the dynamometer2,23,32.
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All testing was performed on the right (dominant) leg. Maximal evoked twitch
and compound muscle action potential (CMAP) responses of the TA were obtained by
supramaximal, percutaneous electrical stimulation of the fibular nerve just distal to the
fibular head. Stimulation was performed through a bar stimulating electrode using single,
100 µs square wave pulses via a constant-voltage electrical stimulator (Digitimer
stimulator, model DS7AH; Digitimer Ltd., Welwyn Garden City, UK). Supramaximal
dorsiflexion twitches were evoked prior to the assessment of voluntary strength.
Participants performed three dorsiflexion maximal voluntary contractions (MVCs), with
at least 3 min of rest between attempts. Participants were instructed to contract as hard
and fast as possible to ensure maximal torque, and rate of torque development were
achieved. Each MVC was held for approximately 3-4 seconds. Participants were
provided with real time visual feedback of their torque on a computer monitor and were
verbally encouraged throughout the contraction. Voluntary activation during the 2nd and
3rd MVC attempts was assessed using the interpolated twitch technique33. This technique
involves supramaximal electrical stimulation of the fibular nerve before, during and after
a voluntary MVC. The amplitude of the interpolated torque electrically evoked from a
single 100µs stimulus during the plateau of the MVC was compared with a single
(100μs) resting twitch evoked ~1s following the MVC. Voluntary activation was
calculated as a percent using the following equation: [1- (interpolated twitch /resting
twitch)] x 100. The twitch evoked following the MVC was used to evaluate postactivation potentiation (PAP) torque. The peak torque of the three MVC attempts was
taken as the maximal torque for the participant. All torque signals were collected and
sampled online at 500 Hz using Spike2 software (Version 7.11; Cambridge Electronic
Design Ltd., Cambridge, United Kingdom) and analyzed off-line to determine voluntary
isometric torques (strength) and voluntary rate of torque development (RTD) (Nm/sec).
Surface electromyography (EMG) was collected from the TA and soleus (SOL)
using self-adhering Ag-AgCl electrodes (1 cm x 3 cm; GE Healthcare, Helsinki,
Finland). For the TA, the active electrode was placed over the motor point, approximately
7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior border of the tibia;
whereas the reference electrode was placed over the distal tendon of the TA. For the
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SOL, the active electrode was placed 2 cm below the gastrocnemii border, along the
longitudinal axis over the soleus; whereas the reference electrode was placed over the
distal tendon of the triceps surae. Electrode placement was adjusted to maximize the TA
and SOL compound muscle action potential (CMAP) negative peak amplitudes as
necessary. Two ground electrodes were placed over the patella. Electrically evoked
CMAPs were elicited from the SOL using a bar electrode held in the distal portion of the
popliteal fossa between the origins of the heads of the gastrocnemius to stimulate the
tibial nerve. Surface EMG signals were preamplified (x100), amplified (x2), bandpass
filtered (10 Hz to 1 kHz), converted by a 12-bit analog-to-digital converter (Power 1401,
Cambridge Electronic Design, Cambridge, UK), and sampled online at 2,000 Hz. To
calculate the level of coactivation, a 0.5 second period of EMG was analyzed from the
SOL corresponding to the point of peak torque during a dorsiflexion MVC. The mean
root mean square (RMS) of this EMG signal was calculated and normalized to the
maximal SOL CMAP (% antagonist coactivation = [mean MVC SOL RMS EMG/peak
RMS SOL CMAP] x 100).
5.2.3

Decomposition-based Quantitative Electromyography (DQEMG) of Tibialis
Anterior
To obtain motor unit number estimates (MUNE) and mean MU firing rates in the

TA, decomposition-based quantitative electromyography (DQEMG) data were acquired
using decomposition enhanced spike triggered averaging (DE-STA) software, described
in detail elsewhere34. Intramuscular EMG signals were recorded via a disposable
concentric needle electrode (Model N53153; Teca Corp., Hawthorne, NY) inserted into
the TA, 5-10 mm distal to the active surface electrode. The surface and intramuscular
EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz, respectively.
Surface EMG was sampled at 3 kHz; intramuscular EMG was sampled at 30 kHz.
Participants matched a target line of 25% MVC, visible on a computer monitor, for all
isometric dorsiflexion contractions while the intramuscular needle electrode was inserted
and manipulated in the muscle. This contraction intensity has been shown to be the most
effective intensity for obtaining a representative motor unit number estimation (MUNE)
in the tibialis anterior (TA) based on the limitations of the technique32. Surface and
intramuscular EMG were collected while participants sustained a steady target torque for
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each contraction held for ~30 s. Between contractions, the concentric needle electrode
was repositioned in order to obtain a sample from different motor units. These procedures
were repeated until at least 20 suitable trains of motor unit potentials (MUPs) and their
respective surface-motor unit potentials (S-MUPs) were collected.
Decomposed EMG signals were reviewed off-line to determine the acceptability
of the needle-detected MUP trains and their corresponding S-MUPs. A computer
algorithm aligned the negative onset markers for all accepted S-MUPs and created a
mean S-MUP template based upon their data-point by data-point average. All MUP and
S-MUP markers were subsequently reviewed visually by the operator. A MUNE was
derived by dividing the negative-peak amplitude of the CMAP by the negative peak
amplitude of the mean S-MUP23 (MUNE = [CMAP/mean S-MUP). In addition to
MUNEs, the DQEMG software measures firing rates (Hz) of individual motor unit action
potential trains (MUAPTs), and provides overall mean firing rates per participant at a
relative target level of contraction. The investigator was blinded to the status of the
participant during off-line analysis.
5.2.4

Magnetic Resonance Imaging of Dorsiflexors
Magnetic resonance images were acquired via serial axial plane in a 3.0 Telsa

magnet (Verio MRI, Siemens; Erlangen, Germany). Proton density images were
acquired using the following parameters: 1500ms repetition time (TR), 14ms echo time
(TE), 256x192 matrix, 243x325mm field of view, 5mm slice thickness with slice
separation of 2mm. Participants were inserted into the magnet bore feet first, in the
supine position, with the motor point on their right TA isocentred to the bore of the
magnet. To ensure minimal movement the feet and knees were strapped together using
inelastic, Velcro straps. The entire musculature of the leg from the tibial plateau to the
malleoli was imaged.
From the images, total TA CSAs were calculated pixel-wise using a combination
of manual and semi-automated techniques with open-source OsiriX image processing
software (version 4.1, Geneva, Switzerland). Muscle CSAs were measured at the slice
with the largest CSA. Analysis began proximally from the first slice, in which the TA
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appeared to the most distal slice containing the TA. A region of interest (ROI) was
manually outlined on the dorsiflexor compartment with the brush tool and repeated every
five slices; missing ROIs on the skipped slices were automatically interpolated. With the
TA outlined, all pixels outside the ROIs were set to zero. To quantify the contractile only
tissue, a three-dimensional threshold-growing tool was used to ensure only muscular
tissue was included in the ROIs (excluding non-contractile tissue and septal spaces). Any
errors produced by the automatic generation were corrected manually. The software
calculated muscle CSA and volume for the ROIs. Sample images of a leg of a control
participant and DPN patient are depicted in Figure 5.1. The investigator was blinded to
the status of the participant during off-line analysis. Previous research has shown a high
degree of intra- (ICC=0.997) and inter-rater reliability (ICC=0.997) with this analysis
technique35. Normalized strength was calculated by relating MVC torque values to TA
CSA (Nm/cm2).

Figure 5.1 Sample magnetic resonance imaging (MRI) images
Sample MRI images of age-matched (~65 year old) male control (A) and diabetic
polyneuropathy (DPN) patient (B) leg. The anterior compartment of the leg is outlined in
white. Note: the greater amounts of intramuscular fatty infiltration and non-contractile
tissue found in the DPN patient leg compared to the control leg (also see Table 5.3).
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5.2.5

Statistics
Mean values ± standard deviations are presented in the text. Normally distributed

data were analyzed using a one-way ANOVA (group); the level of significance was set at
p ≤ 0.05. Normality was assessed using the Shapiro-Wilk normality test; the only variable
found to have a non-normal distribution was mean SMUPs. Non-normally distributed
data were analyzed using a Kruskal-Wallis one-way ANOVA on ranks. Relationships
among variables of interest were testing using Pearson’s Product Moment Correlation.
Data analyses were performed using SigmaPlot software (Version 12.2; Systat Software,
Chicago, Illinois, US).

5.3 Results
5.3.1

Participant Characteristics
Participant characteristics are presented in Table 5.1. No significant differences

were detected for age (p=0.42) or height (p=0.29) between groups. DPN patients had
significantly greater body mass (p=0.008) and BMI (p=0.02) than controls. Data
characterizing the clinical history and status of the DPN patient group are also presented
in Table 5.1.
5.3.2

Dorsiflexor Contractile Properties
Dorsiflexor contractile properties are presented in Table 5.2. DPN patient MVCs

were 35% lower with 48% slower rates of maximal voluntary RTD compared to controls
(p=0.0001), although these differences did not appear to be due to any differences in
voluntary activation (p=0.57). DPN patients featured weaker and slower evoked twitch
responses as evidenced by lesser peak twitch torque (~35%; p=0.02), lesser average rate
of twitch rise (~40%; p=0.01), greater half-relaxation time (~35%; p=0.001) and
greater twitch contraction duration (~22%; p= 0.003). Additionally, the twitch response
of DPN patients potentiated significantly less (~40%; p=0.01) following a 3 second
MVC compared to controls.
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Anthropometric Parameters
Male/Female
Age (years)
Height (m)
Weight (kg)
BMI (kg/m2)
Diabetic Characteristics
Duration of Diabetes (years)
Duration of DPN (years)
HbA1c (%)
Triglycerides (mmol/L)
Cholesterol (mmol/L)
HDL Cholesterol (mmol/L)
LDL Cholesterol (mmol/L)
Total Cholesterol:HDL Ratio
Nerve Conduction Studies
Sural Nerve SNAP Amplitude
(µV)
TA CMAP amplitude (mV)
Fibular nerve CV (m/s)
FDI CMAP amplitude (mV)
Ulnar nerve CV (m/s)

Controls (n = 12)
7/5
64.5 ± 14.7
1.8 ± 0.1
73.8 ± 6.1
24.4 ± 3.1
Range or Limit of Normal
<6.0
0.77-1.7
3.0-5.0
0.9-2.0
2.0-3.0
<5.0

DPN Patients (n = 12)
7/5
65.6 ± 14.6
1.7 ± 0.1
83.1 ± 7.4*
28.9 ± 3.7*
DPN Patients (n = 12)
14.1 ± 11.2
9.2 ± 8.1
7.4 ± 1.4
1.9 ± 1.3
4.1 ± 0.3
1.3 ± 0.5
2.1 ± 0.8
3.9 ± 0.9

Range or Limit of Normal
>5

DPN Patients (n = 12)
1.3 ± 2.5#

>4.0
>40.0
>10.0
>53.0

5.0 ± 1.7
41.4 ± 10.4
10.3 ± 2.7
49.2 ± 3.4

Table 5.1 Participant Characteristics
SNAP – sensory nerve action potential; TA – tibialis anterior; CMAP – compound
muscle action potential; CV – conduction velocity. # SNAP responses were absent in 10
out of 12 patients. * Denotes significant difference between groups (p<0.05).
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Muscle Property
MVC (Nm)
Maximal MVC RTD (Nm/s)
Voluntary Activation (%)
Peak twitch tension (Nm)
Twitch average rate of rise
(Nm/ms)
Time to peak tension (ms)
Half relaxation time (ms)
Twitch Rate of Relaxation
(Nm/ms)
Twitch contraction duration
TPT + HRT (ms)
Potentiated twitch tension
(Nm)
% Potentiation

Control (n = 12)
34.1 ± 9.5
180.5 ± 49.9
98.3 ± 1.9
5.4 ± 1.9
0.05 ± 0.01

DPN (n = 12)
22.3 ± 7.2*
93.9 ± 33.1*
97.6 ± 2.1
3.5 ± 1.3*
0.03 ± 0.01*

% Difference
-34.6%
-47.9%
-35.2%
-40.0%

105.3 ± 17.1
121.8 ± 16.6
0.04 ± 0.01

113.6 ± 25.6
164.3 ± 32.1*
0.02 ± 0.01*

+34.8%
-50.0%

227.1 ± 24.6

277.9 ± 43.9*

+22.0%

8.8 ± 2.7

4.8 ± 1.5*

-45.5%

65.4 ± 22.1

39.7 ± 17.3*

-39.3%

Table 5.2 Dorsiflexion (tibialis anterior) contractile properties in controls and patients
with diabetic polyneuropathy (DPN)
MVC – maximal voluntary contraction; RTD – rate of torque development. * Denotes
significant difference between groups (p<0.05).
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5.3.3

Tibialis Anterior Cross-Sectional Area and Normalized Strength
Both groups featured similar peak absolute TA total size (p=0.21), contractile

tissue (p=0.18), and non-contractile tissue (p=0.14; Table 5.3). However, as a relative
percentage of total size, DPN patients featured 5% less contractile tissue and 5% more
non-contractile tissue (p=0.0003). When normalized to total TA CSA DPN patients were
30% weaker than controls, although total TA CSA contains both contractile and noncontractile tissue (p=0.008; Figure 5.2). However, DPN patients were also found to be
weaker when strength was normalized to maximal TA contractile tissue CSA alone
(p=0.03; Figure 5.2).

Tibialis Anterior Parameter
Total CSA (cm2)
Contractile tissue CSA (cm2)
Contractile tissue CSA (%)
Non-contractile CSA (cm2)
Non-contractile CSA (%)
Strength normalized to total
CSA (Nm/cm2)
Strength normalized to
contractile CSA (Nm/cm2)

Control (n = 12)
10.3 ± 2.3
9.6 ± 2.0
93.2 ± 2.8
0.8 ± 0.4
7.7 ± 2.8
3.5 ± 0.8

DPN (n = 12)
9.5 ± 2.4
8.3 ± 2.2
87.8 ± 4.3*
1.1 ± 0.4
12.2 ± 4.5*
2.5 ± 0.9*

% Difference
-4.8%
+74.3%
-28.6%

3.8 ± 0.6

2.8 ± 0.9*

-26.3%

Table 5.3 Tibialis anterior cross-sectional area and normalized dorsiflexion strength

CSA – cross sectional area; DPN – diabetic polyneuropathy. * Denotes significant
difference between groups (p<0.05).
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5.3.4

Relationships between Muscular Denervation, Function and Morphology
DPN patients featured 25% smaller TA CMAPs (p=0.002), 50% larger mSMUPs

(p=0.03), and 45% reduced MUNEs (p=0.0001) when compared to controls (Table 5.4).
Between groups, no differences were found in antagonist co-activation during MVCs
(p=0.07). In DPN patients, TA MUNEs were negatively related to the proportion of TA
non-contractile tissue (p=0.007, r=0.72; Figure 5.3); whereas no significant relationships
were found between TA MUNEs and contractile/non-contractile tissue in the control
group (p=0.10, r=0.49; Figure 5.3). A significant negative relationship was found
between dorsiflexion twitch half-relaxation time and tibialis anterior MUNEs in the DPN
patient group (p=0.04; r = -0.61), but no significant relationship was found in the control
group (p=0.32, r = -0.31) (Figure 5.4). In the DPN patient group, a negative relationship
was found between antagonist co-activation and dorsiflexion MVC strength (p=0.03, r = 0.64) but not RTD (p=0.24, r = -0.36). During 25%MVC dorsiflexion contractions, mean
TA firing rates were significantly lower in patients with DPN (10 vs 12 Hz; p=0.009).
Finally, within the patient group, mean firing rates were negatively correlated with twitch
half relaxation time (p=0.009, r = -0.77), whereas no significant relationship was found
within the control group (p=0.29, r = -0.36).
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Electrophysiological
Parameter
TA CMAP NP (mV)
TA mSMUP NP (µV)
TA MUNE (#)
Mean TA Firing Rate at
25%MVC (Hz)
MVC % Antagonist (Plantar
Flexor) Coactivation

Control (n = 12)

DPN (n = 12)

% Difference

6.8 ± 0.9
77.0 ± 20.0
99.0 ± 19.0
12.2 ± 1.7

5.0 ± 1.7*
116.0 ± 61.0*
54.0 ± 25.0*
10.1 ± 1.2*

-26.5%
+50.6%
-45.5%
-17.2%

2.7 ± 0.9

4.4 ± 2.4

-

Table 5.4 Needle and surface electromyography of tibialis anterior and plantar flexors
CMAP – compound muscle action potential; NP – negative peak amplitude; mSMUP –
mean surface detected motor unit potential; MUNE – motor unit number estimation;
MVC – maximal voluntary contraction; DPN – diabetic polyneuropathy. * Denotes
significant difference between groups (p<0.05).

107

Figure 5.2 Dorsiflexion specific strength
Dorsiflexion strength normalized to total tibialis anterior (TA) cross-sectional area (CSA)
in controls (solid grey) and diabetic polyneuropathy (DPN) patients (solid black) and TA
contractile tissue CSA in controls (striped grey) and diabetic polyneuropathy (DPN)
patients (striped black). * denotes significant difference between groups (p<0.05).
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Figure 5.3 Relationships between relative tibialis anterior (TA) non-contractile tissue
with TA motor unit number estimations (MUNE)
Controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols).
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Figure 5.4 Relationships between dorsiflexion twitch half-relaxation time and tibialis
anterior (TA) motor unit number estimates (MUNE)
Controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols).
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5.4 Discussion
The main findings of this study were: (1) patients with DPN had significantly
weaker and slowed evoked and voluntary contractile properties of the dorsiflexors; (2) no
differences between groups were found in antagonist co-activation during voluntary
contractions; (3) DPN patients featured less dorsiflexion post-activation potentiation; (4)
DPN patients had less relative contractile tissue and greater relative non-contractile tissue
in the TA than controls; (5) compared to controls, DPN patients featured less specific
strength when torque was related to total TA CSA or contractile TA tissue CSA; (6)
MUNEs were positively related to relative TA contractile tissue CSA (and negatively
related to TA non-contractile tissue CSA) in DPN patients, but not controls.
In the present study, our patient group featured clear evidence of DM and DPN
through elevated glycosylated hemoglobin (HbA1c) levels and reduced or absent sural
nerve sensory nerve action potential amplitudes (SNAPs) (Table 5.1). The slowed
dorsiflexor contractile properties in patients with DPN are consistent with previous
findings reported in rodent models of experimental diabetes9,10,15,19. This contractile
slowing is evidenced by a decreased twitch average rate of rise (-40%), prolonged evoked
half relaxation times (+35%) and contraction durations (+22%), as well as decreased
maximal RTD during voluntary MVCs (-50%) (Table 5.3). In addition to slowing, DPN
patients featured ~40% less post-activation potentiation (PAP) compared to controls
(Table 5.3). Our results may be due to a variety of non-mutually exclusive factors, both
myogenic and neurogenic in nature, and these factors may be directly related to
mechanisms underlying decreases in strength and muscle quality.
5.4.1

Muscle Strength, Quality and Denervation
In humans, it has been well established that DM and DPN are associated with a

loss of muscle mass and strength2,11,36,37. Indeed, our DPN group featured ~35% weaker
dorsiflexion strength than the control group (Table 5.2). In DPN, this weakness is related
to the severity of the neuropathy and is thought to be caused by motor axonal
degeneration and subsequent muscle fibre atrophy2,24. In addition to the present study,
previous reports have shown patients with DM have reduced muscle quality (torque per
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unit of muscle) when compared to healthy controls (Figure 5.2)11,37. Thus, the present
study importantly extends and focuses these previous findings by investigating patients
with DPN, and relating neurogenic changes (i.e. motor axon or motor unit loss) with
changes to muscle morphology. From our results a greater loss of motor units is
associated with greater proportions of non-contractile intramuscular tissue (r = -0.72) and
proportional loss of contractile tissue (r = 0.72) in patients with DPN (Figure 5.3). This
process may be caused by the diabetes-induced denervation of muscle fibres and
insufficiency of surviving motor neurons in providing collateral reinnervation, thus
failing to rescue these orphaned muscle fibres23,24,38. If denervated muscle fibres fail to
acquire a new source of innervation, they may atrophy, die and subsequently the vacated
space may be replaced by intramuscular fat deposits or other non-contractile tissue39–41.
Based on our results, strength and muscle quality differences cannot be attributed
to differences in voluntary activation of the TA, as both groups were able to activate their
muscle similarly, and near maximally (>95%). Additionally, no differences were found
between groups for antagonist co-activation during voluntary MVCs (Table 5.4).
However within the DPN group, there was a significant negative relationship (r = -0.64)
between antagonist co-activation % and strength, thus perhaps with greater disease
severity antagonist co-activation may become more pronounced to help stabilize the
ankle joint during contraction. Alternatively, this pattern of weakness and increased coactivation may be related to a loss of proprioception associated with DPN42. In either
case, changes in agonist-antagonist co-activation in DPN patients seem comparable to
contraction strategies used in other patient populations with neurological disorders such
as stroke, muscular dystrophy and Parkinson’s disease16,17. Finally, myocellular gene
expression of key contractile and regulatory proteins are markedly reduced in diabetes,
particularly in the absence of insulin (and presumably established insulin resistance as
occurs in type 2 DM)43. Some of these down-regulated genes control the synthesis of
myosin heavy chain polypeptide, myosin light chain, actin, troponin, tropomyosin and
calmodulin proteins 43. In a single myocyte, reduced transcription of these genes could
result in less contractile (e.g. actin, myosin) and contractile-supporting proteins (e.g.
troponin, tropomyosin), potentially resulting in less tension produced per muscle fibre.
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5.4.2

Muscle Contractile Slowing and DPN
Conflicting results have been reported from studies that have explored the impacts

of diabetes on muscle fibre type composition, which is important pertaining to contractile
speed and post-activation potentiation (PAP). Using an experimental animal model of
diabetes, one investigation showed slow oxidative muscle fibres were least affected by
DM, whereas fast oxidative and fast glycolytic muscle fibres were reduced in proportion
and size44. In contrast, using human cross-sectional studies, patients with non-insulindependent DM (type 2 DM) have been reported to possess lower proportions of type I
muscle fibres and greater proportions of type II fibres (especially type IIb) in skeletal
muscle (vastus lateralis) compared to healthy controls45,46. It is important to note that the
animal model of experimental diabetes44 represented type 1 DM in humans, whereas the
muscle fibre composition studies in humans investigated patients with type 2 DM. Thus
the latter may better reflect the physiological status of the patients included in the present
study, who had type 2 DM. Given this information, faster contractile properties might be
expected to accompany DM, contrary to the results presented in this study. However, it is
possible changes in excitation-contraction (EC) coupling and Ca2+ handling supersede the
effects of muscle fibre type and MHC expression on contractile speed, or they are
competing factors which are differently expressed depending on the muscle or disease
severity. Indeed, it is important to note the durations of diabetes in the studies that tested
human vastus lateralis (VL) muscles45,46 are unknown, and the VL is a relatively
proximal muscle that may be less affected (versus TA) by the length-dependent
neurogenic changes associated with DPN. The muscle fibre compositions in the patients
included in those prior studies with more recent disease onset may be more a reflection of
the risk of development of DM as opposed to the effects of DM on potential muscle fibre
type changes47. Additionally, studies investigating muscle fibre composition and DM
have not explored the impacts of DPN on this relationship.

Although motor unit or axon loss is a feature of DPN2,23,24,38 it is not known
whether there is a preferential loss of larger, faster (type 2) motor units. If type 2 motor
units are lost preferentially, this could drive the observed slowing of muscle contractile
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properties via the collateral reinnervation of orphaned muscle fibres by slow, type 1
motor neurons. Subsequently, these reinnervated muscle fibres acquire the characteristics
of their new parent motor neuron48. Indeed, there is some evidence to suggest this may be
the case in DPN. For example, our results show a negative relationship between MUNEs
and dorsiflexion twitch half-relaxation time (r = -0.61). This relationship could reflect a
slowing of muscle properties due to a preferential loss of faster motor units associated
with muscular denervation (Figure 5.4). The significantly lesser degree of PAP in
muscles from DPN patients reported in this study may also reflect a greater proportional
loss of fast, type 2 motor units because muscle potentiation is known to be heavily
influenced by fibre type composition49. Also, motor unit firing rates are reduced in DM
and DPN patients at a given contractile intensity in both the TA (Table 5.4)23 and vastus
lateralis25 which may indicate a preferential loss of faster motor units, or slowing of the
firing rates of surviving motor units. This process matches the contractile slowing
reported in the present study and corroborates findings in healthy development and
aging27,28. Additionally, within the DPN group, prolonged twitch half-relaxation times
were negatively associated with decreases in mean firing rates (r = -0.77), however it is
not known if one alteration is necessarily dependent on the other.
Changes in EC coupling and Ca2+ handling may partially be responsible for
slowing of contractile properties of patients with DPN. It has been reported previously
that baseline myocellular Ca2+ levels are elevated in diabetic rats50. Even relatively minor
increases in myocellular Ca2+ concentrations have been demonstrated to cause attenuation
in the rate of Ca2+ release from the sarcoplasmic reticulum (SR) during contraction51,52,
and therefore a lower rate of SR Ca2+ release could directly lead to a decrease in RTD in
evoked or voluntary contractions. Additionally, muscles from diabetic rodents may
possess elevated SR Ca2+ ATPase activity levels and increased microsomal Ca2+ uptake
capacity53. This increased sequesterization and reuptake of Ca2+ may impose further
limitations on Ca2+ interaction with the actin-myosin contractile complex, resulting in the
reduced RTD in the muscles of the DPN group compared with controls found in our
study. However, increased reuptake of Ca2+ by the sarcoplasmic reticulum would
presumably result in an increased rate of relaxation, which is contrary to the results
reported in the present study.
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Additional considerations regarding the reported reductions in strength and
slowed contractile properties in patients with DPN include alterations in muscle
architecture and tendon mechanical properties. Whereas aspects of muscle architecture,
such as pennation angle, fascicle length and sarcomere number and orientation, were not
directly measured in this study, the increased proportion of non-contractile tissue in the
TA of DPN patients may reflect broader architectural changes. Heterogeneous
development of intramuscular non-contractile tissue and fatty infiltration12 may not only
reduce muscle CSA, but it may also disrupt normal fascicular organization. Structurally,
an important determinant of whole muscle contractile speed is the number of sarcomeres
in series54, and fascicular disruption via non-contractile tissue could result in contractile
slowing. With regard to tendon mechanical properties, previous studies have found the
tendons of DM and DPN patients appear to show signs similar to those undergoing
accelerated aging55,56. Specifically, these changes include altered tendon fibril shape,
increases in fibril packing density, and increased tendon stiffness55,57. However, these
DM-related changes in tendon properties are unlikely to lead to a slowed or weaker
contractile response as a stiffer tendon would be conducive to a faster RTD. Slowed
contractile properties as a result of DPN may be related to important functional
decrements in conjunction with strength loss; specifically impaired muscle power
generation. As power is a function of both muscle torque generating capacity and
contractile velocity, a decrease in either or both aspects will lead to reductions in power.
Indeed, previous reports show patients with DM feature a loss of isokinetic power
generation relative to controls, and the degree of power loss is greater than reductions in
torque generating capacity12,36. Additionally, this loss of power in DPN patients may be
more important than strength loss alone in terms of functional consequences in dynamic
muscle activities and the onset of physical disability58. Finally, one possible confound
related to our findings regarding contractile slowing is the potential difference between
groups in physical activity levels. A previous study has shown that with adult aging, more
sedentary individuals demonstrate greater contractile slowing than those who are more
physically active59. We do not report a direct quantification of physical activity history of
our participants, however both our controls and nearly all of our DPN patients were
living independently in the community with no mobility issues (2 DPN patients had
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impaired mobility and utilized a wheelchair or a cane). We do not believe there were
substantive differences in everyday physical activity levels between the two groups.
Thus, whereas a lesser engagement in physical activity may be responsible for some of
the slowing observed in our patient group, we believe the primary reason underlying the
reported contractile differences is due to DPN itself, not reduced physical activity levels.
5.4.3

Summary
The present study reports contractile slowing, loss of muscle CSA, loss of

strength and reduced contractile quality of lower limb muscles in association with DPN
in humans. We propose these neuromuscular alterations may be caused by a combination
of factors related to both myogenic and neurogenic changes that are known to occur with
DPN. However, the relationships between muscle morphology and contractile slowing
with denervation (MUNE) suggests changes in muscle properties may be secondary to
neurogenic processes. With regards to functional consequences, these findings may
represent key underlying mechanisms leading to DPN-related impairments in gait11,60,
impaired balance and increased fall risk61,62, and reduced walking speed62.
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CHAPTER 6
6

Increased fatigability associated with severe diabetic neuropathy is
attributed partially to neuromuscular transmission failure5

6.1

Introduction
Diabetic polyneuropathy (DPN), a common complication of diabetes mellitus

(DM), can be associated with dysfunction of the neuromuscular system. Some DPNrelated neuromuscular changes include: muscle atrophy1, weakness2, muscle contractile
slowing3, reduced motor unit firing rates4–6, and motor unit loss5,7,8. However, at present,
little is known regarding how these alterations may affect the performance of the
neuromuscular system when its capacity is stressed during a fatiguing task and
subsequent recovery. Challenging the compromised system will permit the identification
and functional relevance of key underlying factors contributing to DPN.
Neuromuscular fatigue can be defined as the loss of voluntary force-producing
capacity during physical activity9. In the context of this investigation, this is
differentiated from “experienced fatigue” which refers to a general sense of tiredness,
lack of energy or chronic exhaustion often reported clinically10,11. Neuromuscular fatigue
is well known to be task-dependent and can be affected by a wide array of factors
including age12, physical training status13 and neurological disease14.
One previous study that explored muscle fatigue in insulin dependent (type 1)
DM, concluded DM patients have greater relative muscle endurance than controls during
repeated, maximal isokinetic contractions of the ankle plantar and dorsiflexors15.
However, in that report, the majority of DM patients either did not have symptoms of
DPN or had a neuropathy with minimal motor involvement15. Additionally, no measure
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of voluntary activation was made, therefore it is not known whether participants were
producing maximal efforts during their isokinetic contractions15. It has been shown
previously that individuals with metabolic disease without neuropathy (e.g. type 1 DM)16,
vascular disease (e.g. chronic heart failure)17, or nerve disease (e.g. amyotrophic lateral
sclerosis [ALS])18, fatigue more quickly than controls.
Greater fatiguability in various other clinical populations when compared with
controls has been attributed to a range of factors including: insufficient blood flow17,
impaired neuromuscular transmission19, and central activation failure20. Indeed, even
during minimally fatiguing contractions (25% MVC for 30 seconds), neuromuscular
conduction failure has been reported in DPN patients (Chapter 4). In contrast, healthy
adult aging has been associated with greater resistance to fatigue in most isometric
tasks12,21, but not all isometric tasks and muscle groups22. It is not entirely clear whether
slowed contractile and metabolic functions often reported with aging necessarily provide
greater endurance23, in any case, slowed contractile properties also have been reported in
DPN patients which could theoretically impart the same effect on fatigability3. However,
because DPN can involve concurrent pathophysiological changes to metabolism,
vasculature, and nerve and muscle, the impact of altered contractile properties may be
mitigated. Therefore, DPN provides an interesting model to study various factors
contributing to fatigue as well as to improved understanding about the functional impact
of DPN.
Investigating the recovery of neuromuscular properties following fatigue also can
provide insight into underlying physiological processes, although it is typically less well
studied than fatigue per se. Metabolic disturbances24, blood flow impairments25 and
dysfunction in myocellular processes related to clearing metabolites and restoring
homeostasis26,27 could conceivably impair or delay recovery in DPN patients.
The present study used a sustained, isometric dorsiflexion maximal voluntary
contraction (MVC) to induce fatigue to a predetermined task termination point (i.e.
60%MVC). Dorsiflexion was selected because the dorsiflexors (i.e. tibialis anterior) are
known to be affected in DPN3,5,7, and participants are readily able to maximally activate
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the dorsiflexors, with minimal familiarization or training28. A sustained, isometric MVC
was selected to provide a relatively simple model that would substantially stress the
neuromuscular system29,30. Finally, a pre-determined task termination point (60%MVC)
was utilized to ensure all participants fatigued to the same degree relative to their
maximal strength, thus providing an opportunity to assess recovery30.
Thus the main objective of this study was to investigate neuromuscular fatigue in patients
with DPN compared to age-matched controls using a sustained, dorsiflexion MVC. We
also aimed to determine whether impairments in neuromuscular transmission or voluntary
activation were associated with fatiguability in the DPN group. An additional objective
was to assess the short-term (i.e. 2 minute) neuromuscular recovery of DPN patients
compared to controls. We hypothesized individuals with DPN would fatigue more slowly
than controls due to reduced absolute strength and slowed muscle contractile properties.
Additionally we hypothesized both groups would be able to achieve near maximal
voluntary activation (~95%) while fatiguing to 60% of MVC torque. Finally, we
hypothesized DPN patients would recover more slowly than controls following the
fatigue protocol due to DPN-related dysfunction in metabolite clearance and blood flow.

6.2 Methods
6.2.1

Participants
Ten patients (6 males) with DPN (aged 64 ± 11 yrs) and ten age- and sex-matched

controls (aged 62 ± 12 yrs) were recruited for participation in this study. All participants
provided informed, written consent prior to participation. The study was approved by the
local university’s Research Ethics Board and conformed to the Declaration of Helsinki.
The patients with DPN met accepted clinical criteria for diagnosis of DM and DPN31.
The presence of DPN was confirmed via clinical and electrophysiological examination
performed by a trained neurologist, who also confirmed the absence of other causes of
nerve injury or neuropathy. Data outlining some of the neuromuscular impacts of DPN
(e.g. loss of motor units, muscle slowing, and neuromuscular transmission instability) in
these patients have been previously reported elsewhere3,5. Patients with metabolic,
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neurological or vascular conditions unrelated to DM or DPN were excluded from
participation. Data regarding glycemic control were obtained through clinical chart
review. Control participants were living independently in the community, free from
medications and were screened by physicians (neurologists) to ensure they met inclusion
criteria. Participants in both groups were not engaged in systematic physical exercise
regimens.
6.2.2

Evoked Contractile Properties and Maximal Strength of Dorsiflexors
The experimental set-up has been described in detail in previous reports3,5.

Participants were seated in a custom isometric dorsiflexion dynamometer to assess
voluntary and electrically evoked properties of the dorsiflexor muscles32. In all
participants the right leg was tested. The ankle was positioned at 30° of plantar flexion;
both knee and hip angles were positioned at 90°. Hip joint movement was minimized by
securing a padded, adjustable brace over the distal aspect of the right thigh. Inelastic
straps were wrapped over the dorsum of the foot to secure it to the dynamometer33. The
great toe was left uncovered by the straps to minimize torque contributions from extensor
hallucis longus.
Maximal evoked single twitch and compound muscle action potential (CMAP)
responses from the dorsiflexors (tibialis anterior muscle) were obtained using
supramaximal electrical stimulation of the fibular nerve just distal to the fibular head.
Percutaneous nerve stimulation was performed using a bar electrode which transmitted
the single, 100 µs square wave pulses triggered from a constant-voltage electrical
stimulator (Digitimer stimulator, model DS7AH; Digitimer Ltd., Welwyn Garden City,
UK). Twitches were analyzed off-line for: peak twitch tension (Nm), time to peak tension
(ms), and half-relaxation time (ms). From these data twitch contraction duration (CD
[ms]; time to peak tension + half-relaxation time) and twitch rate of torque development
(RTD (peak twitch tension/time to peak twitch tension)) were calculated. Accompanying
CMAPs were analyzed for maximal peak to peak voltage (mV).
At least 3 dorsiflexion, maximal voluntary contractions (MVCs), and no more
than 5, were performed by each participant, and each MVC attempt was separated by at
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least 3 minutes to minimize the development of any fatigue before the actual fatigue test.
Participants were verbally instructed to perform their MVC as hard and as fast as possible
to ensure maximal torque and rate of torque development were produced. MVCs were
held for ~3-4 seconds during each attempt, during which strong verbal encouragement
was given. Real time visual feedback of the torque signal was provided to the participant
on a computer monitor throughout the experimental protocol. The interpolated twitch
technique (ITT) was used to assess voluntary activation (VA) during the 2nd and 3rd MVC
attempts to ensure adequate muscle activation was achieved34. The ITT involves
supramaximal electrical stimulation of the fibular nerve before, during and immediately
after a voluntary MVC. The amplitude of the interpolated torque electrically evoked
during the plateau of the MVC was compared to the twitch elicited immediately
following the MVC. VA% was calculated as: [1- (interpolated twitch /resting twitch)] x
100. The peak torque measured during the 3 MVC attempts was recorded as the maximal
torque for that participant. All torque signals were collected and sampled online at 500
Hz using Spike2 software (Version 7.11; Cambridge Electronic Design Ltd., Cambridge,
United Kingdom). Torque was later analyzed off-line to determine voluntary isometric
torques (strength) and maximal voluntary rate of torque development (RTD (Nm/s)).
Maximal RTD was obtained by transforming the torque signal into its first derivative and
recording the peak value for a given contraction.
Throughout the experimental protocol surface electromyography (EMG) was
recorded from the TA and soleus (SOL) muscles using self-adhering Ag-AgCl electrodes
(1 cm X 3 cm; GE Healthcare, Helsinki, Finland). For the TA, the active electrode was
placed over the motor point, approximately 7 cm distal to the tibial tuberosity and 2 cm
lateral to the anterior border of the tibia; the reference electrode was placed distally over
the tendon of the TA. For the SOL, the active electrode was placed 2 cm below the
gastrocnemii border, along the longitudinal axis over the soleus; the reference electrode
was placed distally over the tendocalcaneus. Minor adjustments to active electrode
placement over the TA were made until the optimal CMAPs (greatest amplitude and
fastest rate of rise) were obtained from percutaneous, supramaximal nerve stimulation.
Ground electrodes were placed over the patella. Maximal SOL CMAPs were obtained by
electrically stimulating the tibial nerve between the origins of the heads of the
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gastrocnemeii muscles. Surface EMG signals were pre-amplified (x100), amplified (x2),
bandpass filtered (10 Hz to 1 kHz), converted by a 12-bit analog-to-digital converter
(Power 1401, Cambridge Electronic Design, Cambridge, UK), and sampled online at
2,000 Hz.
6.2.3

Fatigue Protocol
Following the assessment of maximal dorsiflexion strength participants rested for

10 minutes to ensure any fatigue or post-activation potentiation had dissipated. The
fatigue protocol in the present study involved a single, sustained, isometric dorsiflexion
MVC. The MVC was maintained until the participant could no longer sustain 60% of
their pre-fatigue MVC torque. For the fatigue protocol, participants were instructed to
contract as hard and as fast as possible, and as long as possible. Additionally participants
were instructed to minimize any extraneous movements or contractions aside from
dorsiflexion; also they were asked to continue breathing throughout the fatigue protocol.
During the fatigue task, participants were provided with continuous and strong verbal
encouragement. Throughout the protocol visual feedback of their torque was provided on
a computer monitor. In addition to torque output, the computer monitor displayed a
horizontal lines demarcating 100% of MVC and 60% MVC. Task termination occurred
when the torque dropped and remained below the 60% MVC level despite further verbal
encouragement. Participants were not informed that the line on the computer monitor
demarcating 60% of MVC torque represented their task termination point. Prior to
instructing the participant to cease the fatiguing MVC, an interpolated twitch was applied
to assess VA% at task termination.
Similar to baseline measures, fatigue protocol torque and EMG data were
analyzed offline. Time to task termination was determined as the time from which the
participant reached their maximal torque until they could no longer produce torque
greater than 60% of their baseline MVC. Torque and TA EMG data from the fatigue
protocol were subsequently binned into increments of 10% of their time to task
termination (i.e. a fatigue protocol lasting 60 seconds would consist of 10 x 6 second
bins). Average torque and TA RMS EMG data for these 10% bins were calculated for
each participant. Binned torque and RMS EMG data were subsequently normalized to
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MVC torque and maximum RMS EMG data, respectively. This served to provide profiles
of torque output and neural activation of the TA over the course of the fatigue protocol.
Antagonist (soleus) co-activation was quantified during the dorsiflexion MVC fatigue
protocol in similar manner to TA activation, but was normalized to soleus RMS EMG
during baseline MVCs. The area under the curve of the torque tracing was measured to
assess the angular impulse (Nm x sec) for each participant. This served as an analogue for
the parameter of work, which is often calculated for dynamic muscle contractions. VA%
at the cessation of the fatigue protocol was calculated similarly to baseline MVCs,
described above. A sample fatigue protocol is depicted in Figure 6.1.
6.2.4

Assessment of Recovery
Immediately (~1 second) following cessation of the fatigue protocol a

supramaximal electrical stimulus was applied to the fibular nerve to help assess the
degree of central and peripheral fatigue induced by the fatigue protocol. Subsequently,
participants performed MVCs with ITT at 30 seconds and 2 minutes post-fatigue
protocol. Prior to these MVCs, additional maximal dorsiflexion twitches were elicited to
provide an assessment of recovery of the twitch and CMAP properties following fatigue.
MVCs were assessed for VA% using the ITT technique. Recovery MVC torques and TA
EMG data were analyzed similarly to baseline MVCs.
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Figure 6.1 Raw torque and EMG tracings from fatigue and recovery protocol
Sample torque, tibialis anterior root-mean-squared electromyography (RMS EMG) and plantar flexor RMS EMG during a sustained,
isometric dorsiflexion maximal voluntary contraction (MVC) fatigue protocol, and subsequent recovery at 30 seconds and 2 minutes
post-task termination.
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6.2.5

Statistical Analysis
Mean values ± standard deviations are presented in the text, tables, and figures,

except where noted. The level of significance was set at p ≤ 0.05 for all statistical tests.
All baseline data, and time to task termination of the fatigue protocol were analyzed
using a one-way ANOVA (group). Binned torque and EMG values for fatigue data, as
well as recovery data were analyzed using a mixed design (split-plot) ANOVA. For these
mixed design ANOVAs the between-subjects factor was group (control or DPN patient),
with repeated measures over time. Fatigue and recovery data were analyzed both as
absolute values, as well as relative to baseline. Mauchly’s sphericity test and Levene’s
test were used to ensure there were no violations of sphericity or homogeneity of variance
assumptions, respectively. Main and interaction effects were determined by Pillai’s trace
(p ≤ 0.05). Following each ANOVA in which a significant main effect or interaction was
found, post-hoc analysis was performed using the modified Bonferroni correction
method. Relationships among variables of interest were testing using Pearson’s Product
Moment Correlation. Data analyses were performed using IBM SPSS Statistics software
(Version 20.0; IBM SPSS, Arnock, New York, USA).

6.3 Results
6.3.1

Participant Characteristics and Baseline Measures
Participant characteristics are presented in Table 6.1. No differences between

groups were found for age (p>0.05), height (p>0.05), or weight (p>0.05). Baseline
neuromuscular measures are presented in Table 6.2. DPN patients were found to have
40% weaker (p<0.05) MVCs with 47% slower maximal RTD (p<0.05). Strength
differences were not due to differences in VA% (p>0.05). Compared with controls, the
DPN group twitches were ~36% smaller (p<0.05), and ~25% slower (i.e. longer
contraction durations) (p<0.05) with ~40% smaller CMAP peak to peak amplitudes
(p<0.05).
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Participant Characteristic
Males/Females
Age (years)
Height (m)
Weight (kg)
HbA1c (%)

Controls (n=10)
6/4
62.2 ± 12.1
1.6 ± 0.1
71.4 ± 5.6
-

DPN Patients (n=10)
6/4
64.7 ± 11.3
1.6 ± 0.1
78.9 ± 8.5
7.5 ± 1.2

Table 6.1 Participant Characteristics
DPN – diabetic polyneuropathy

Torque Parameter
MVC Torque (Nm)
MVC RTD (Nm/s)
Voluntary Activation
(%)
Peak Twitch Torque
(Nm)
Time to Peak Twitch
(ms)
Twitch RTD (Nm/s)
Half-Relaxation Time
(ms)
Contraction Duration
(ms)
EMG Parameter
CMAP Negative Peak
Amplitude (mV)

Controls
33.7 ± 8.1
170.2 ± 41.5
98.8 ± 2.1

DPN Patients
20.2 ± 9.2*
89.1 ± 37.9*
97.2 ± 3.7

% Difference
-40%
-47%
-

5.1 ± 1.7

3.2 ± 1.8*

+36%

106.2 ± 17.1

116.2 ± 28.6

-

45.0 ± 17.0
122.0 ± 15.0

28.0 ± 14.0*
170.2 ± 25.0*

-42%
+40%

228.0 ± 23.0

286.0 ± 42.0*

+25%

6.6 ± 0.7

4.6 ± 1.1*

-30%

Table 6.2 Dorsiflexion neuromuscular parameters at baseline

MVC – maximal voluntary contraction; RTD – rate of torque development; contraction
duration = time to peak twitch + half-relaxation time; EMG – electromyography; CMAP
– compound muscle action potential. * Denotes significant difference between groups
(p<0.05).
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6.3.2

Fatigue
Fatigue profiles of torque over time are presented as absolute values in Figure 6.2.

The mean time to task termination of the fatigue protocol was ~21% shorter in DPN
patients (56.4 ± 14.2 sec) compared to controls (71.1 ± 11.7 sec; p = 0.001). Additionally,
DPN group angular impulse was ~50% less than controls (1637.4 ± 639.7 vs 852.4 ±
410.5 Nm*s; p<0.05). There was a main effect for time (p<0.05) and an interaction effect
for group and time (p<0.05) for the changes in relative torque calculated from the binned
time intervals. Both groups featured decreases in torque output relative to their baseline
MVCs over the course of the fatigue protocol (p<0.05). Pairwise comparisons between
groups over binned time intervals showed the DPN group had lesser decreases in relative
torque output from 50-90% of the time to task termination compared to controls (p<0.05).
Just prior (1-2 s) to task termination VA% was >95% in both groups (p>0.05). No
significant relationships were found between glycemic control (i.e. HbA1c %) or severity
of neuropathy (i.e. TA CMAP amplitude) and time to fatigue.
In both groups over the course of the fatigue protocol, TA RMS EMG normalized
to MVC RMS EMG values are expressed over 10% binned time intervals in Figure 6.3.
For these variables a main effect of time (p<0.05) and an interaction effect between time
and group (p<0.05) were detected. From 0-30% of the time to task termination, the DPN
group featured less relative EMG activity from the TA compared with controls. For the
remainder of the fatigue protocol no differences were detected in relative TA RMS EMG
between groups (p>0.05). There were no group differences (p>0.05) in % antagonist
soleus coactivation during the fatigue protocol, however there was an effect of time
(p<0.05) with both groups featuring decreased % antagonist coactivation over the fatigue
protocol (results not shown).
6.3.3

Recovery
Absolute data pertaining to neuromuscular recovery following the fatiguing

protocol are found in Table 6.3. At thirty seconds post-fatigue both DPN patients and
control groups featured MVCs that were significantly weaker (~10%) compared to
baseline (p<0.05; Table 6.3), but these relative changes were not different between

132

groups (p>0.05). At 2 minutes post-fatigue, the MVC for both had recovered to baseline
levels (p>0.05). Similarly, MVC RTD was significantly reduced (~20%) in both groups
30 seconds following fatigue (p<0.05; Table 6.3), however both groups were not
significantly different from their respective baselines at 2 minutes post-fatigue (p>0.05).
VA% was near maximal (>95%) in both groups during MVCs at 30 seconds and 2
minutes post-fatigue (p>0.05).
The twitch evoked immediately following task termination was 15-20% weaker in both
groups relative to their respective baseline twitches (p<0.05; Table 6.3), however the
relative changes were not different between groups (p>0.05; Figure 6.4A). Peak twitch
torque recovered to baseline levels in both groups at 30 seconds post-fatigue (p>0.05).
Twitch half-relaxation time (HRT) was prolonged ~20% compared to baseline in both
groups immediately following the fatigue protocol (p<0.05; Table 6.3), and at 30 seconds
post-fatigue twitch HRT recovered in both groups.
Peak to peak CMAP amplitude was significantly reduced by ~12% in DPN
patients immediately following the fatigue protocol (p<0.05; Figure 6.4B); whereas for
controls there was no change (p>0.05; Figure 6.4B). By 30 seconds post-fatigue, the DPN
group CMAPs had recovered to baseline (p<0.05).
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Figure 6.2 Fatigue protocol: absolute torque over time
Mean absolute dorsiflexion torque (Nm) produced during a sustained, isometric
dorsiflexion maximal voluntary contraction (MVC) fatigue protocol in controls (open
symbols; time to task termination = 71 s) and diabetic polyneuropathy (DPN) patients
(closed symbols; time to task termination = 56 s). * denotes significant difference
between groups in time to task termination (p<0.05). Controls produced significantly
greater torque throughout the protocol (p<0.05).
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Baseline
Controls

DPN
Patients

Immediate Post Fatigue
Controls

DPN
Patients

30 sec Post Fatigue
Controls

DPN Patients

2 min Post Fatigue
Controls

DPN Patients

Twitch
Torque (Nm)

5.1 ± 1.7

3.2 ± 1.8*

4.1 ± 1.3§

2.8 ± 1.7*§

4.6 ± 1.3

3.3 ± 1.9*

5.0 ± 1.6

3.3 ± 1.7*

Twitch HRT
(ms)

122 ± 15

170 ± 25*

145 ± 21§

203 ± 23*§

120 ± 13

172 ± 29*

124 ± 18

184 ± 43*

MVC (Nm)

33.0 ± 8.0

20.0 ± 9.0*

-

-

30.6 ± 9.4§

17.6 ± 7.9*§

32.9 ± 10.1

19.6 ± 9.0*

MVC RTD
(Nm/s)

170.2 ± 41.5

89.0 ±
37.9*

-

-

135.1 ± 50.1§

65.8 ±
26.9*§

166.4 ± 52.7

86.6 ± 30.9*

6.6 ± 0.7

4.6 ± 0.9*

6.2 ± 0.7

4.0 ± 0.5*§

6.2 ± 0.7

4.4 ± 0.6*

6.4 ± 0.8

4.4 ± 0.7*

CMAP Peak
to Peak Amp
(mV)

Table 6.3 Absolute recovery of maximal twitch, MVC and CMAP
DPN – diabetic polyneuropathy; HRT – half-relaxation time; MVC – maximal voluntary contraction; RTD – rate of torque
development; CMAP – compound muscle action potential. * denotes significant difference between groups; § denotes significant
difference from baseline (p<0.05)
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Figure 6.3 Tibialis anterior electromyography activity during fatigue task
Tibialis anterior relative root-mean-squared electromyography (RMS EMG) during a sustained, isometric dorsiflexion maximal
voluntary contraction (MVC) fatigue protocol in controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed
symbols). * denotes significant difference between groups (p<0.05).
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Figure 6.4 Twitch torque and compound muscle action potentials following fatigue
protocol
Electrically evoked dorsiflexion relative twitch torques at baseline, immediately post-task
termination, 30 seconds post-task termination and 2 minutes post-task termination in
controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols). §
denotes significant difference from baseline. (4B) Relative peak to peak compound
muscle action potential (CMAP) amplitudes (mV) at baseline, immediately post-task
termination, 30 seconds post-task termination and 2 minutes post-task termination in
controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols). §
denotes significant difference from baseline; * denotes significant difference between
groups (p<0.05).
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6.4 Discussion
The main findings of this study were: (1) during a sustained isometric dorsiflexion
MVC, those with DPN had less endurance compared to controls; (2) the differences in
fatiguability between groups did not appear to be due to deficiencies in VA%; (3) DPN
patients featured evidence of possible neuromuscular transmission failure during and
immediately following the fatiguing task, whereas controls did not; (4) at 2 minutes postfatigue, the maximal evoked and voluntary contractile properties of the dorsiflexors in
both groups had recovered similarly to baseline levels.
6.4.1

Increased Fatiguability in DPN
In agreement with other studies, baseline neuromuscular properties of the

dorsiflexors related to strength (MVC, MVC RTD, twitch torque) and CMAP amplitude
were decreased in patients with DPN compared to controls (Table 6.2)3,5,35,36. However
novel to the present study, when tasked with maintaining a sustained, isometric
dorsiflexion MVC, those with DPN fatigued significantly more quickly (~21%)
compared to controls. Furthermore, the difference in fatigability between groups did not
appear to be due to differences in VA, as both groups maintained greater than 95% VA
(p>0.05) as measured via the interpolated twitch technique at task termination. The time
to task failure of the control group was similar to that reported previously using this same
task and protocol (71 vs 85 s)29, but the greater endurance of the control group did not
seem to be due to any differences in voluntary activation, as both groups achieved >95%
voluntary activation just prior to task termination. Moreover, the greater muscle
endurance in the control group does not appear to be due to a pacing strategy as their
RMS EMG indicates a maximal or near-maximal effort and follows the expected pattern
for a sustained MVC (Figure 6.3).
DPN patients fatigued significantly more quickly (~21%; Figure 6.1), while
producing lower absolute torques, and substantially lesser total angular impulse (~50%)
compared to controls. However, our results stand in contrast to those previously reported
in a study investigating fatigue in a mixed population of insulin-dependent (type 1) DM,
with and without DPN in which DM patients had greater muscular endurance than
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controls15. The divergent findings could be accounted for by several key differences in
experimental design. Andersen (1998)15 investigated fatigue in a group of insulindependent DM patients, many of whom reported no symptoms of DPN or featured a mild
DPN with minimal motor involvement. The present study included non-insulindependent DM patients (type 2 DM), all with substantial neuromuscular impairment of
the dorsiflexors3,5. Moreover, there are important differences in the underlying alterations
related to DPN and metabolism in insulin-dependent versus non-insulin-dependent DM37.
Additionally, the prior study used a metric of fatigue that combined plantar and
dorsiflexor performance which may have affected the results given the greater resistance
of the plantar flexors to DPN-related changes relative to the dorsiflexors. Finally, the
previous work used repeated isokinetic contractions which are difficult to assess in terms
of voluntary activation and their intermittent nature could attenuate the development of
any substantive neuromuscular transmission failure.
There are several possible mechanisms underlying the increased fatiguability
observed in DPN patients, which are not mutually exclusive. One possible mechanism is
the presence of neuromuscular transmission failure, which may occur at the motor axon,
neuromuscular junction or muscle fibre membrane. Evidence supporting transmission
failure is reflected by the decreased relative surface EMG activity during fatigue in the
DPN group compared to controls (Figure 6.3), and a reduction in CMAP size
immediately following fatigue in DPN but not in controls (Figure 6.4B). Failure to
propagate action potentials at any point in the neuromuscular system would fail to cause
contractions of the associated muscle fibres, thus limiting the system’s force generating
capacity. Demyelination or axonal damage could lead to a reduced safety factor and
action potential propagation failure in the motor axon in a manner similar to frequency
dependent conduction block observed in other demyelinating neuropathies38,39.
Furthermore, given the significant reduction in motor units in DPN patients5,7,8 any
neuromuscular transmission failure occurring at the level of the motor axon may have
exacerbated decrements in force production compared to other demyelinative conditions
because each remaining motor unit innervates a greater relative proportion of muscle
fibres following motor unit loss and subsequent collateral reinnervation. DPN-related
pathological alterations at the neuromuscular junction (e.g. reduced numbers of synaptic
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vesicles) or muscle fibre (e.g. T-tubule disruption) levels could also contribute to failed
neuromuscular transmission40. In addition, dysfunctional axonal Na+/K+ pumps27,41 and
myocellular Ca2+ channels42,43 may contribute to any conduction failure in DPN, as
previously postulated41. Moreover, neuromuscular transmission failure has been
previously reported in DPN during sustained (i.e. 30 seconds) low intensity (25% MVC)
contractions (Chapter 4). Thus it is possible the sustained maximal contraction used in the
present study could result in equal or greater transmission failure, reducing force
generation capacity in DPN patients more quickly than controls during a sustained
contraction.
Another potential cause underlying the increased fatiguability in DPN observed in
the present study is related to abnormal muscle energy metabolism. A previous report has
documented that myocellular PCr loss and pH decrease occur significantly faster during
low intensity plantar flexion exercise, in skeletal muscle of type 2 DM compared to
healthy controls24. Additionally, deoxygenation during exercise occurred more quickly in
type 2 DM than controls24. Greater PCr loss, increased myocellular inorganic phosphate
concentrations and decreased pH in DPN patients compared to controls could lead to an
earlier reduction in actomyosin cross-bridge force production during a sustained effort
(see Westerblad et al 1998 for review44). However, it is important to note that the
aforementioned report discussing skeletal muscle energetics in DM during exercise used
repeated dynamic contractions during a protocol that lasted ~7 minutes24, which is a very
different exercise duration and contraction type compared to the present study. Indeed,
the task-dependent nature of fatigue has been well-described (see Enoka and Duchateau
2008 for review45) therefore it is not completely clear how these previous findings may
relate to the results presented here.
An additional consideration regarding DPN and skeletal muscle endurance is
related to blood supply. Adequate blood flow is necessary to engage in oxidative
metabolism, and if this blood flow is insufficient during muscular contraction,
metabolism and the ability to remove metabolic by-products which inhibit force
production are limited44. It has been reported that DM and DPN are associated with
dysfunction in the macro- and microvasculature25,46–49, as well as oxygen kinetics during
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exercise50,51. Although blood flow to the dorsiflexors may not present a major limitation
to force production in healthy individuals52, it should be noted that an impaired ability to
deliver oxygen and clear metabolites from contracting muscle could contribute to
increased fatiguability in DPN patients.
6.4.2

Neuromuscular Recovery Post-Fatigue in DPN
DPN patients performed a fatigue protocol of shorter duration (~21%; Figure 6.2),

at lower absolute levels of torque output (~40%; Figure 6.2), and therefore markedly less
total angular impulse (~50% less angular impulse) compared to controls. Two minutes
following fatigue evoked twitch and MVC properties had returned to baseline values in
both groups. However, immediately following the fatigue protocol, DPN patients and
controls both featured evoked twitch responses that were similarly weaker than their
respective baseline twitches (Figure 6.4A). Additionally, 30 s post-task termination both
groups had similar deficits in MVC torque (~10%) and MVC maximal RTD (~20%). The
similar recovery profiles between patients and controls are surprising giving the
substantial disparity in total angular impulse (i.e. work), and it may be interesting to test
these groups with tasks of equal total angular impulse. Notwithstanding, whereas fatigue
induced a similar relative change in twitch torque across groups, it appears that the
reasons underlying the weaker twitch responses may be different. DPN patients featured
a smaller CMAP compared to baseline, whereas the mean CMAP from the control group
was unchanged immediately following fatigue (Figure 6.4B). This finding could indicate,
as mentioned earlier, neuromuscular transmission failure may have occurred in DPN
patients contributing to a decrease in strength; whereas twitch torque depression in
controls is likely primarily due to accumulation of force depressing metabolites (e.g.
inorganic phosphate, H+ ions). Another consideration is DPN patients have been shown
to potentiate to a lesser relative extent (~-40%) compared to healthy controls3, which may
be related to muscle atrophy53 or changes in fibre type composition54. As individuals with
DPN benefit less from post-activation potentiation, they may be more subject to the
force-depressing effects of fatigue without gaining as much from the competing forceincreasing effects of potentiation during recovery55. In summary, to recover from a
maximal, sustained fatiguing contraction of short duration, it seems DPN patients may
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need to regain both neuromuscular transmission fidelity, as well as the clearance of
metabolites, as evidenced by prolonged half-relaxation times.
6.4.3

Summary
The present study reports an increased susceptibility to neuromuscular fatigue in

patients with diabetic neuropathy compared to controls, during sustained maximal
contractions. Given our results, we propose this DPN-related greater fatiguability may be
partially attributed to neuromuscular transmission failure and possibly pathological
alterations in muscle metabolism affecting cross-bridge force production. Although the
DPN group performed approximately 50% less angular impulse (an isometric analogue of
work) than controls, post-fatigue, evoked and voluntary muscle strength properties
recovered in both groups similarly. These findings may have functional relevance
underlying abnormal gait and increased fall risk in patients with DPN56,57. Finally, DPNrelated fatiguability may warrant consideration for the design and implementation of
exercise-based rehabilitation strategies for this patient population.
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CHAPTER 7
7

General Discussion and Summary

7.1

General Discussion

This thesis provided substantial novel experimental evidence regarding the effects
of diabetic polyneuropathy (DPN) on the neuromuscular system in humans. The first half
of this thesis focused on DPN-related changes at the motor axon and neuromuscular
signal transmission level. Indeed, my results support the concept of a DPN-related loss of
motor units (Chapters 2 & 3) and neuromuscular transmission instability with intermittent
signal propagation failure (Chapter 4). Moreover, the second half of this thesis
investigated how these alterations at the motor axon and neuromuscular transmission
levels affect skeletal muscle properties and function. I reported the degree of motor unit
loss is related to increased non-contractile intramuscular tissue and muscle slowing
(Chapter 5); and DPN is associated with increased fatiguability in the context of a
sustained maximal contraction, which may be related to neuromuscular transmission
failure (Chapter 6). These findings (1) build upon the understanding of how DPN may
impact the neuromuscular system; (2) help explain DPN-related functional limitations;
and (3) eventually may prove useful in the diagnosis and progressive assessment of DPNmotor system involvement in clinically or rehabilitative settings.
The studies included in this thesis confirm and extend the understanding of how
DPN may affect the neuromuscular system. It has long been understood that DPN can
cause neuromuscular dysfunction, and it has been presumed part of this dysfunction was
due to neuromuscular remodeling and the loss of motor axons1,2. Indeed, this notion
forms the basis for using compound muscle action potential (CMAP) amplitude, and
needle electromyography (EMG)-detected motor unit potential (MUP) parameters as
electrophysiological markers of neuropathy in DPN patients1,3,4. Moreover, one previous
study reported DPN may be associated with motor unit loss in the extensor digitorum
brevis (EDB), an intrinsic muscle of the foot2. In this thesis, the results in Chapters 2 and
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3 extend the concept of motor unit loss in DPN by exhibiting reduced MUNEs in the
tibialis anterior (TA) in DPN patients versus controls. This finding is important as it
shows DPN can impact motor unit numbers in a more proximal muscle, with a more
fundamental functional role, compared to EDB. Also, studying the TA rather than EDB is
warranted because it may be difficult to ascertain whether EDB motor units are damaged
due to neuropathic stressors or mechanical damage caused by the altered gait associated
with DPN5,6. Furthermore, the results presented in Chapter 3 indicate DPN-related motor
unit loss and remodeling may follow a similar distal to proximal pattern of progression as
other aspects of DPN7.
This thesis also builds upon previous work suggesting DPN patients could be
susceptible to neuromuscular transmission failure (Chapter 4). Various studies using
animal models of DPN have found dysfunction in motor axons, the neuromuscular
junction, and muscle fibres, all of which may contribute to failed action potential
propagation8–11. Additionally, in humans, Na+/K+ pump dysfunction and reductions in
nodal Na+ currents have been suggested as having the potential to trigger conduction
failure12,13. In Chapter 4 of this thesis, I report intermittent conduction failure in the form
of % blocking, as well as unstable neuromuscular transmission, supporting the concept
that transmission failure may occur in patients with DPN. Moreover, this susceptibility to
transmission failure could have functional implications, specifically with regards to a
reduced capacity to sustain intense efforts, as presented in Chapter 6.
The effect, if any, of DM or DPN on motor unit or muscle fibre type composition
is not clear14–18. Previous studies have suggested there is an increase in the relative
proportion of type II or fast motor units in animal models or patients with DM14,15,18.
However those results may not reflect the chronic effect of DPN, but rather the physical
inactivity associated with the development of diabetes mellitus (DM). Additionally those
studies may have been influenced by technical limitations associated with the procedures
used to assess muscle fibre type19. The results in Chapter 4 of this thesis indicate the
sensible possibility that DPN preferentially targets type II motor units. This is evidenced
by: slowed evoked contractile properties, reduced voluntary rates of torque development,
and reduced motor unit firing rates compared to controls (Chapter 4). This can be
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interpreted to indicate that in terms of neuromuscular changes, DPN acts like an
accelerated form of human aging20. However, these aforementioned DPN-related
alternations could be caused by a host of other factors (e.g. reduced numbers of
sarcomeres in series or increased tendon compliance reducing muscle speed), and further
study is required to parse out the physiological causes underlying these results.
DPN patients often feature various functional limitations which may affect their
ability to live independently, and decrease their quality of life. These can include: altered
or slowed gait5,21,22, impaired standing and dynamic balance23, increased fall risk29,
increased risk of injurious falls24, an inability to do housework25, and difficulty climbing
stairs25. These functional limitations have been associated with the presence and severity
of neuropathy26, however it is important to consider that dysfunction in the different
compartments of the nervous system may have inter-related, synergistic effects. For
example, lower limb muscle weakness (secondary to motor unit loss)2,7, in conjunction
with loss of sensation27 and deficits in proprioception28 likely all play contributing roles
in altered gait patterns and increased prevalence of falls29. Furthermore, patients with
DPN with substantial dorsiflexor weakness and impaired sensation are at increased risk
of developing ‘foot drop’5,6,21 and their foot drop is more likely to cause them to trip and
fall29–31. As outlined in this thesis, the notion that DPN is associated with reduced muscle
speed16,32, and hence reduced muscle power32,33, may further exacerbate the impaired
functional capacity of DPN patients, beyond strength loss alone34. Additionally, the
increased susceptibility to neuromuscular fatigue may impact the ability of this group to
engage in sustained or repeated activity (i.e. climbing up many flights of stairs, engaging
in an exercise-based rehabilitation or training program)35,36. For example, some of the
findings described in this thesis, particularly loss of muscle strength, speed and
endurance, should be taken into consideration when developing or managing preventative
and rehabilitative training programs. For example, in terms of rehabilitative strategy, a
training program for those with DPN may feature a greater emphasis on maintaining both
muscle mass and muscle power to help prevent the functional decline outlined above34,37–
40

.

150

Given the nature and extent of the potential DPN-related impacts on the
neuromuscular system, early diagnosis may be integral to forming the optimal plan for
treatment and prevention. Some of the findings presented in this thesis may prove helpful
in contributing to the early identification and longitudinal assessment of DPN, especially
in the context of neuromuscular involvement7 (Chapters 2-4). In Chapters 2 and 3, DPN
was shown to be associated with a loss of motor units, which was correlated with a loss
of strength41. Interestingly, the majority of patients with DPN included in these studies
had CMAPs greater than 4.0 mV and thus would not have met the electrophysiological
clinical threshold for pathological motor involvement of the TA. However, when
examining individual TA MUNEs in this group compared to healthy age matched
controls, the DPN group generally appeared to possess substantially fewer motor units
despite maintaining a clinically ‘normal’ or ‘healthy’ sized CMAP. Between groups, TA
MUNEs had a larger magnitude of effect (or effect size) than CMAPs or needle EMGderived measures of neuromuscular pathology (Chapter 3). Additionally, the NF MUP
parameters introduced in Chapter 4 may prove useful in an EMG clinic setting,
particularly when higher intensity contractions are performed during a clinical needle
EMG study, which may be desirable to allow for a MUNE calculation. However, it is
important to note the comparisons performed in Chapters 3 and 4 between MUNE, NF
MUP parameters and more standard electrophysiological markers of disease are
somewhat limited and biased. The results used to represent standard MUP parameters, for
example, were not obtained using the same protocol that would be used in the EMG
clinic. Additionally, the DPN patient group studied throughout this thesis featured a more
severe neuropathy, with a more drastic motor component, than what would be expected
in patients in the very early stages of DPN3,42,43. Thus further study is warranted to better
evaluate the novel electrodiagnostic parameters described herein to determine their
potential diagnostic and prognostic utility.
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7.2 Limitations
Many of the conclusions throughout this thesis were made based upon results
obtained using electrophysiological methods, particularly analysis of DQEMG. Some of
these conclusions could have been better supported or confirmed had I included muscle
biopsies in my studies. For example, the analysis of muscle biopsies could have:
supported the idea of neuromuscular remodeling (via fibre type grouping)44; given insight
into any shift of muscle fibre type predominance19,20; or provided greater understanding
of muscle quality (via the assessment of single myofibre properties)45,46. However, the
inclusion of muscle biopsies was not practical for these experiments. Moreover, the
majority of my projects focused on the dorsiflexor muscle group, especially the TA,
which is not considered a convenient muscle to biopsy compared with the knee extensors,
for example. Obtaining and analyzing vastus laterali biopsies would provide a specious
and spurious means for comparison with the TA, given the length-dependent nature of
DPN, and the different properties and functions of these muscle groups. Additional
methodologies that could have added further insight into these studies are magnetic
resonance spectroscopy (MRS) or near-infrared spectroscopy (NIRS). The use of MRS or
NIRS would have been particularly helpful in Chapter 6, the study of DPN and fatigue, as
these might have elucidated the accumulation of metabolites47 (inorganic phosphate, H+
ions etc) and level of deoxygenation48 throughout the fatigue and recovery protocols.
However, the inclusion of these techniques was not a practical or feasible addition with
the design of these original studies.
Habitual physical activity levels play important roles in muscle strength, muscle
speed49,50, and perhaps the age-related rate of neuromuscular remodeling and motor unit
loss51,52. The DPN patient and control groups discussed in this thesis were not matched
for physical activity levels, nor was physical activity level quantified using
questionnaires, accelerometers or some other method. This must be considered when
interpreting any of the results presented herein. If the control group was substantially
more physically active than the DPN group, this difference could conceivably contribute
to some of the divergence between the groups with respect to their neuromuscular
properties and health. However, if the DPN group was substantially less active than the
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controls, one would likely expect to find faster evoked muscle twitch properties in the
DPN group often reported in models of disuse53,54 (Chapter 5). Rather, the twitch
responses of the DPN patients were significantly slower than the controls (Chapter 5).
Furthermore, anecdotally, the majority of patients with DPN appeared to maintain
relatively ‘average’ physical activity levels for their age. Finally, although the control
group may have engaged in more physical activity on a day-to-day basis than the DPN
group, they were not engaged in systematic physical training and their activity levels
likely were not so high as to cause a notable effect on neuromuscular properties.
Additionally, the mean participant ages were approximately 65 years old. The
effects of natural adult aging on the neuromuscular system are thought to manifest
detectably in most individuals in the 7th decade of life55. Thus, the majority of those in the
DPN group studied in this thesis would not only be expressing DPN-related changes but
also age-related changes to the neuromuscular system. This may affect the
generalizability of the results obtained in this thesis, as DPN may differentially affect
humans as they age, versus how DPN may affect a group of homogenously young
participants. Furthermore, both experimental groups included similar equal numbers of
males and females. Although the two groups were sex matched, the inclusion of both
sexes may have introduced greater heterogeneity into our dataset. Unfortunately due to
challenges with subject accrual, an insufficient number of DPN patients of both sexes in
these studies precludes an examination of any sex-based differences in the effects of DPN
on the neuromuscular system.
As mentioned earlier in this section, my conclusions regarding physiological
mechanisms are generally derived from obligatory indirect measurements, including
EMG, electrically evoked muscle properties, MRI, and dynamometry. In forming
conclusions regarding DPN-related underlying changes to the neuromuscular system,
such indirect measures are not necessarily ideal. However, although the specific
mechanisms cannot be obtained with certainty using these techniques, this does not
invalidate them or prevent their interpretation in the context of previous studies using
animal models, reduced preparations or more invasive means in humans. Moreover, it
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may emphasize the need for, and influence the direction of future studies which
ultimately need to be explored in the human model.

7.3 Future Directions
There are a plethora of interesting and viable avenues for future research
concerning the impacts of DPN on the neuromuscular system, the description of which
will be necessarily somewhat limited in this section. Future studies may build upon my
conclusion that DPN causes reduced motor unit firing rates and muscle slowing by
recording maximal motor unit firing rates. This could be accomplished by recording
motor unit firing rates intramuscularly using tungsten needle electrodes. Furthermore,
tests of the force-velocity relationship, maximal contractile velocity and isotonic muscle
power generation might greatly add to the understanding of DPN-related impacts on
muscle function. This could be carried out using the isokinetic or, preferably, isotonic
modes of a Cybex or Biodex multi-joint dynamometer. Additionally, such dynamic
contractions used in the context of a fatigue protocol may allow for a better
understanding of the limitations placed upon skeletal muscle affected by DPN. In
conjunction with these measures, it would be helpful to include standard clinical
measures of mobility or functional capacity, including sit-stand tests, shuttle walks, and
tests of balance. Additionally, metrics, such as questionnaires, assessing physical activity
history could provide useful information regarding the status of participants. Inclusion of
such measures may help delineate the functional relevance of the various parameters
tested in those with DPN in the neuromuscular laboratory.
To help identify and quantify the presence of neuromuscular transmission failure
it would interesting to apply single motor unit recordings during sustained and fatiguing
contractions in DPN patients. Including this measure could provide a more robust
indicator of intermittent transmission failure of individual motor units, which would be
more persuasive than relying upon the analysis of surface EMG or post-contraction
CMAPs alone. Furthermore, this technique may be used during sustained, ramped
contractions providing insight into the recruitment and de-recruitment patterns of patients
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with DPN compared to controls. Repetitive nerve stimulation could also be used to test
for neuromuscular transmission failure at rest or during fatigue.
Throughout this thesis, no limitations regarding voluntary activation during
maximal efforts (including the fatigue protocol) were identified in controls or DPN
patients. However, inclusion of transcranial magnetic stimulation (TMS) or
cervicomedullary (CM) stimulation would provide further insight into any DPN-mediated
changes at the supraspinal or spinal levels of excitability. Examining changes in the silent
period following stimulation, or the amplitudes of motor evoked potentials (MEP) or
cervicomedullary motor evoked potentials (CMEP) under various conditions would
provide some insight into the influence of these important factors.
Finally, a longitudinal study of patients with DPN, including the neuromuscular
parameters outlined in this thesis, could provide greater insight into the progression of
DPN-related neuromuscular dysfunction. Concurrent assessments of the sensory and
autonomic nervous system also would be helpful in determining how neuropathy
progresses in the different aspects of the nervous system. Perhaps most interestingly, a
longitudinal study would provide an opportunity to assess the ameliorative, restorative or
preventative effects of exercise training. Previous studies have investigated the effects of
resistance and/or aerobic training on other aspects of DM or DPN: including glycemic
control56, vascular function57, development of neuropathy58, autonomic dysfunction59,60
and balance and gait61. However, the effects of training on neuromuscular impacts of
DPN are less well understood, thus specifically it would be fascinating to assess how
different training modalities and intensities affect the motor progression of DPN. In this
context, to investigate how a resistance training regimen focused on training and
restoring speed and power, in addition to strength, compares to a more traditional
approach to exercise in DPN could be interesting. And finally, the potential
neuroprotective effects of chronic exercise51,52 in DPN patients should be assessed.
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7.4 Summary

Diabetic polyneuropathy (DPN) may cause many impactful physiological and
functional alterations to the human neuromuscular system. My thesis consists of an
integrated collection of novel and foundational studies concerning DPN. Specifically, it
provides support for the importance of the progressive and accelerated loss of motor units
underlying muscle atrophy and weakness in patients with DPN (Chapters 2 and 3).
Indeed the accelerated loss of motor units is associated with the development of
intramuscular non-contractile tissue, the loss of contractile muscle mass, and the slowing
of muscle contraction (Chapter 5). In addition to the loss of motor units, my thesis
indicates there is a loss of fidelity or stability in those motor units that remain (Chapter
4). This DPN-related neuromuscular instability may be associated with, and perhaps a
precursor to, neuromuscular transmission failure during intense, sustained bouts of effort
(Chapter 6). Overall these foundational explorations may help direct further useful
studies and strategies to understand, and influence clinical support in those with DPN.
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